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Abstract 
The Role of PI3K/AKT/TSC/p70S6K1 Pathway    
in Tumor Growth and Angiogenesis 
          Qiao Meng 
 
PI3K/AKT pathway plays an important role in tumor progression and 
angiogenesis.  To determine the specific role of PI3K isoform p110α in ovarian cancer, 
we designed small interfering RNA (siRNA) against p110α.  The expression of p110α 
siRNA significantly decreased cell migration, invasion, and proliferation.  AKT has 
three different isoforms: AKT1, AKT2 and AKT3.  We found that downregulation of 
AKT1 is sufficient to inhibit cell migration, invasion, and proliferation in ovarian cancer 
cells. The activation of p70S6K1 was decreased in both p110α and AKT1 
siRNA-expressing cells.  Inhibition of p70S6K1 activity also decreased cell migration, 
invasion, and proliferation.   
The tuberous sclerosis complex-2 (TSC2) lies upstream of mTOR/p70S61 and 
downstream of AKT.  Loss of TSC2 expression is observed in human cancer.  To study 
the function of TSC2 in ovarian tumor angiogenesis, we established stable cell lines that 
express siRNA specific to TSC1 and TSC2.  In this study, we show that inhibition of 
TSC1 and TSC2 increased the expression of HIF-1α in ovarian cancer cells.  Inhibition 
of TSC1 and TSC2 upregulated VEGF expression at both mRNA and protein levels.  
Downregulation of TSC2 induced ovarian tumor angiogenesis and tumor growth through 
mTOR/p70S6K1.  The expression of p70S6K1 siRNA decreased VEGF protein 
expression and VEGF transcriptional activation through the HIF-1α binding site.  The 
expression of p70S6K1 siRNA specifically inhibited HIF-1α expression in ovarian 
cancer cells.  We also found that p70S6K1 down-regulation decreased ovarian tumor 
growth and tumor angiogenesis.  This study provides a novel molecular mechanism of 
human ovarian cancer induced by the activation of p70S6K1.   
Survivin gene is highly expressed in ovarian cancer cell lines and is a potential 
target of gene therapy for ovarian cancer.  Our study showed that expression of survivin 
siRNA induced cell apoptosis when combined with LY294002 or taxol treatment. We 
determined that suvivin mRNA is regulated by PI3K/AKT/p70S6K1 pathway.  Survivin 
is an important downstream molecule of PI3K/AKT/p70S6K1 pathway that plays a role 
in antiapoptosis in ovarian cancer cells.   
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Introduction 
Phosphatidylinositol-3-kinase (PI3K) plays an important role in cell proliferation, 
differentiation, anti-apoptosis, tumorigenesis and angiogenesis.  PI3K are activated by 
receptor tyrosine kinases, and activation of PI3K has been implicated in several human 
cancers.  Recently PIK3CA was found to be the only gene affected by somatic 
mutations in a mutational screen of eight PI3K genes and eight PI3K-like genes 1.  
PIK3CA, the gene encoding the p110α catalytic subunit, has somatic mutations in many 
cancers including gastric adenocarcinoma 2, brain cancers 3, colorectal carcinomas 4, 
breast cancer and ovarian cancer 5 .  PI3KCA is also frequently increased in copy 
number in 40% of ovarian cancer cell lines and patient tumor samples 6.  Mutations of 
the phosphatase and tensin homologue (PTEN) tumor-suppressor gene are frequently 
detected in glioblastomas, prostate cancer and endometroid epithelial cancer 7.  An 
important downstream target of PI3K is the serine-threonine kinase AKT.  AKT1 
kinase activity is frequently elevated in ovarian cancer.  P70S6K1 is activated through 
the PI3K pathway, the MAPK pathway and TSC/mTOR pathway 8-10.  Gene encoding 
for p70S6K1 is also amplified in ovarian cancer cells 11 and its p70S6K1 kinase is 
constitutively phosphorylated in ovarian cancer cells.  P70S6K1 is known to play a 
role in cell proliferation, cell size and cell cycle progression, but little is known about its 
role in angiogenesis.  This research work is to study the roles and mechanism of TSC2 
and p70S6K1 in regulating tumor growth and angiogenesis. 
Survivin is a new member of the inhibitor of apoptosis gene family.  Increased 
survivin expression is a negative prognostic marker in many tumors, including ovarian 
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cancer 12-14.  Survivin plays an important role in anti-apoptosis.  However it remains 
to be elucidated how PI3K/AKT/p70S6K1 pathway regulates survivin expression and 
what the role of survivin in ovarian tumor growth is. 
This research work provides us with the data to determine the role of PI3K 
downstream targets TSC, p70S6K1 and survivin in tumor progression. 
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Literature Review 
І.  The PI3K/AKT signaling pathway and tumorigenesis 
The PI3K family consists of a large family of lipid and serine/thronine kinases. 
Class IA PI3Ks are composed of heterodimers of an inhibitory adaptor/regulatory (p85) 
and a catalytic subunit p110.  The SH2 domain of p85 has two functions: activation of 
small G protein and relief of trans-inhibition of p110.  The catalytic p110 subunit has 
both serine-thronine protein kinase activity 15 and phosphoinositide kinase activity 16.   
The activation of PI3K/AKT pathway is commonly triggered by the activation of 
receptor tyrosine kinases in response to the stimulation of growth factors that leads to 
the autophosphorylation on tyrosine residues and transphosphorylation of adaptor 
proteins.  Activation of PI3K occurs upon binding its SH2 domains of the p85 
regulatory subunit to specific tyrosine residues on the activated receptor or associated 
adaptor proteins.  This leads to the translocation of PI3K from cytoplasm to plasma 
membrane and the activation of p110α catalytic subunit17.  Activated PI3K can add a 
phosphate group to the D3-OH position of the inner membrane phosphoinositides 
leading to the production of the second messengers PI-3, 4-biphosphate and PI-3, 4, 
5-triphosphate (PIP3)18.  These lipids have a high affinity to the pleckstrin-homology 
domain of AKT and PDK1.  This binding recruits AKT from the cytoplasm to the 
plasma membrane19.  The translocation of AKT to plasma membrane can result in a 
conformational change of AKT that exposes two amino acids: threonine 308, which is 
phospharylated by PDK120; serine 473, which is phosphorylated by PDK221.  The 
phosphorylation of these two amino acids is necessary for the activation of AKT.  AKT 
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transmits signal to many target proteins that are involved in the control of apotosis and 
cell proliferation.  The termination of PI3K pathway is mediated by two different types 
of phosphatases.  The SH2 containing inositol phosphatase (SHIP) dephosphorylates 
PIP3 at position D5, producing PI-3, 4-biphosphate22.  Phosphatase and tensin 
homolog (PTEN) acts as an antagonist to remove the phosphate group at the D3 position 
and convert PIP3 back to PI-4, 5-biphosphate23.  
There are three known isoforms of Class IA p110 (p110α/p110β/p110δ) and 
seven known p85/p55 subunits generated by alternative splicing of three genes 
(p85α/p85β/p85γ).  Biochemical and gene knock out studies suggest that different 
isoforms mediate specific signaling pathway and have different functions24-26.  PI3K is 
an enzyme involved in many cellular processes.  Its activity has been linked to cell 
survival, cell proliferation, cell cycle progression, protein synthesis, cell transformation, 
cytoskeleton organization and angiogenesis27.  PI3K was first reported as an oncogene 
by the analysis of the avian sarcoma virus 16 (ASV 16) genome.  ASV16 encodes an 
oncogene that is derived from the cellular gene for the catalytic p110α subunit of PI3K.  
The viral p110α gene has PI3K activity.  Subcutaneous injection of one-day-old 
chickens with chicken embryo fibroblasts transfected with the viral chicken p110α 
cDNA in an avian retroviral expression vector RCAS, RCAS-v-P3K, resulted in the 
induction of hemangiosarcomas at the injection site in two weeks 28.  Abnormalities in 
the PI3K pathway are common in cancer.  PI3K is a frequent target of mutation.  
PIK3CA, the gene encoding the p110α catalytic subunit, has somatic mutations in 74 of 
199 colorectal cancers (32%), 4 of 15 glioblastomas (27%), 3 of 12 gastric cancers 
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(25%), 1 of 12 breast cancers (8%), and 1 of 24 lung cancers (4%) 29.  Somatic 
missense mutations were also observed in 24 of 198 (12%) ovarian carcinomas, and in 
13 of 72 (18%) breast carcinomas5.  The gene copy number of the p110α catalytic 
subunit of PI3K is frequently increased in ovarian cancers 6,30.  Although p85α 
mutation is rare, a mutated form of the p85 subunit of PI3K has been detected in a 
human lymphoma cell line31.  PTEN and AKT are also targets of frequent genomic 
changes in human cancers.  PI3K antagonist PTEN is frequently mutated in many 
human cancers such as glioblastoma, melanoma, endometrial cancer, prostate cancer, 
breast cancer and ovarian carcinoma 7,10,32-35.  AKT is a very important downstream 
target of PI3K.  AKT has three different isoforms that have been implicated in specific 
functions in cancer36.  AKT2 plays an important role in cell motility and invasion37.  
AKT3 has a role in hormone independence.  AKT amplification or overexpression is 
found in some human cancers38-42.  A 20 fold amplification of AKT1 is found in a 
primary gastric adenocarcinoma 43.  AKT2 was shown to be amplified and 
overexpressed in ovarian carcinomas 38, pancreatic cancer 40 and breast carcinomas 44.  
AKT3 was found to be upregulated in estrogen receptor negative tumors and 
androgen-independent prostate cancers 45.  AKT is activated by growth factor signaling 
through PI3K and strongly enhances cell growth and proliferation by phosphorylating 
regulators of cell cycle, apoptosis, metabolism and cell growth and translation.  
Activation of AKT has also been reported in a wide variety of human cancers.  AKT 
activation has been shown to correlate with advanced disease and/or poor prognosis in 
some tumor types46-50.   
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II. The PI3K/AKT pathway and angiogenesis 
The role of PI3K in angiogenesis, an important process involved in 
neovascularization, has been established51.  Tumor growth and metastasis were 
proposed to be angiogenesis-dependent in 197152.  Angiogenesis is the generation of 
new blood vessels derived from the existing vasculature53.  Tumor vasculature is 
highly disorganized.  Vessels are tortuous and dilated with excessive branching and 
shunts. Tumor angiogenesis is a highly regulated process that is controlled genetically 
by alterations in oncogene and tumor suppressor gene expression and physiologically by 
the tumor microenvironment.  Vascular endothelial growth factors (VEGF) are the 
most powerful angiogenic cytokines in many cancers.  VEGF expression is regulated 
by tissue oxygen content54,55 and by growth factors and cytokines, including 
platelet-derived growth factor56, epidermal growth factor57, insulin, insulin-like growth 
factor-I58, and tumor necrosis factor α59.  VEGF transcription is regulated by many 
transcription factors that include AP-160, NF-κB61 and hypoxia-inducible factor 1 alpha 
(HIF-1α)62.  Hypoxia is the major physiological stimulus for VEGF expression.  
Hypoxia stimulates VEGF expression through gene transcription55, mRNA stablization63 
and translational regulation64,65.  The transcriptional regulation of VEGF is mediated 
by HIF-1α66.  HIF-1 regulates both hypoxia- and growth factor-induced VEGF 
expression in tumor cells.  Activated receptor tyrosine kinases increase HIF-1α protein 
synthesis through PI3K/AKT/mTOR pathway and ERK mitogen-activated protein 
kinase (MAPK) pathway67-69.  Activation of oncogene Ras70 and the activation of PI3K 
pathway stimulate the expression and secretion of VEGF in tumor cells67,71.  
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PI3K/AKT pathway regulates the expression of VEGF mediated by HIF-1α independent 
of hypoxic condition in tumor cells72.  The inhibitor of PI3K LY294002 or the mTOR 
inhibitor rapamycin inhibited secretion of VEGF by growth factors in prostate cancer 
cells and this effect linked the EGF/PI3K/PTEN/AKT/FRAP pathway to angiogenesis73.  
Similarly, LY294002 reduced both constitutive and hypoxia-inducible levels of VEGF in 
ovarian carcinoma cells74.  In addition, overexpression of the v-P3k protein or of 
cellular PI3K with a myristylation signal, Myr-P3k, can induce angiogenesis in the 
chorioallantoic membrane (CAM) of the chicken embryo.  Overexpression of the 
myristylated form of the PI3K target Akt, Myr-Akt, also induces angiogenesis.  
Moreover, the VEGF mRNA level is elevated in cells expressing activated PI3K or 
Myr-Akt75.  AKT has effects on tumor-induced angiogenesis that is mediated partially 
through hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor 
(VEGF).  AKT can also preferentially increase the rate of translation of VEGF 
mRNA76,77.  Activation of AKT can lead to the stablization of HIF-1α and increased 
production of VEGF via mTOR/FRAP in breast73 and prostate cancer cells69.  PTEN is 
also involved in tumor angiogenesis.  PTEN can induce secretion of thrombospondin-1, 
a negative regulator of angiogenesis78.   
 
III. TSC and tumor angiogenesis 
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder and is 
characterized by the development of hamartomas, which is unusual tumor-like growth 
found in the central nervous system, kidney, heart, lung and skin79.  Considerable 
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progress has been made in understanding the molecular genetics of TSC, highlighted by 
the identification of the two-tumor suppressor genes tsc1 and tsc280,81.  The tsc1 and 
tsc2 genes encode the protein hamartin and tuberin 82.  Mutation of either TSC gene 
leads to the development of the heritable disorder TSC.  The TSC genes undergo loss 
of heterozygosity(LOH) in the majority of the TSC lesions83.  LOH in TSC 
gene-associated regions is also frequently observed in neoplasms such as 
angiomyolipoma, lymphangiomyomatosis 84, renal cell carcinoma85 and lung 
adenocarcinoma with multiple atypical adenomatous hyperplasis 86.  
Genetic studies in Drosophila show that TSC1 and TSC2 take part in the control 
of cell size via the insulin/p70S6K pathway87.  TSC2 encodes a protein of 200 kDa, 
TSC2 (also called Tuberin), which is ubiquitously expressed and localized to the 
perinuclear Golgi88.  TSC2 forms a complex with TSC1 that negatively regulates 
mammalian target of Rapamycin (mTOR)89.  Recent biochemical analyses confirmed 
that tuberin is a substrate of AKT 90 and can regulate PI3K-dependent activation of 
p70S6K91.  AKT is activated by growth factors and phosphorylates TSC2, which 
disrupts TSC2 binding to TSC1.  TSC2 acts as a GTPase-activating protein for Rap1 
and Rab592.  Disruption of TSC2/TSC1 complex allows for activation of mTOR.  
Activated mTOR phosphorylates 4E-BP and S6 kinase, leading to an increase in the 
rates of protein translation93.  
One common phenotype of the TSC lesions is the highly angiogenic vascular 
vessel in the benign and malignant tumors.  Abnormal blood vessels can be found in 
angiomyolipomas and cutaneous angiofibromas85.  Several studies suggested that TSC 
 10
plays a role in the regulation of angiogenesis.  Loss of tuberin is accompanied by 
increased levels of HIF-1α and VEGF 94.  Inactivation of TSC2 results in the 
accumulation of HIF-2α and upregulation of VEGF in rat renal cell carcinoma 95.  
TSC2 regulates VEGF through mTOR-dependent and -independent pathways96.  
 
IV. P70S6K1 and tumorigenesis  
P70S6K1 is an important regulator of cell proliferation and cell growth.  The 
70kDa ribosomal S6 kinase (p70S6K) is activated by PI3K and MAPK.  Full activation 
of p70S6K1 requires phosphorylation of T229 by PDK197 and phosphorylation by T389, 
possibly by mTOR98,99.  Growth factors such as insulin, PDGF and EGF can activate 
p70S6K1 through the activation of PI3K and AKT 100.  PI3K activation is necessary 
and sufficient for the activation of p70S6K1 which specifically phosphorylate the 
ribosomal protein S6 required for cells to enter the S phase after mitogenic stimulation 
101
.  Activated PI3K or AKT can induce cell transformation through the 
phosphorylation and activation of p70S6K1 102.  P70S6K1 regulates cell growth by 
inducing protein synthesis components.  The physiological target of growth factor 
activated p70S6K1 is the 40s subunit of the S6 ribosomal protein.  Phosphorylation of 
S6 induces the selective translation of 5’ tract of pyrimidines (5’ TOP) mRNA, a subset 
of mRNA that contains an oligopyrimidine tract at its 5’ untranslated region.  The 5’ 
TOP mRNA encodes components of the translational machinery such as elongation 
factors, ribosomal proteins and poly (A)-binding protein103. 
It has been suggested that p70S6K1 is involved in tumor progression.  A recent 
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finding in expression profiles of cancer cells is the upregulation of mRNAs that code for 
ribosomal proteins, suggesting involvement of p70S6K1104.  A marked increase in 
p70S6K mRNA and protein expressions have been demonstrated in breast cancer cell 
lines as well as in primary breast tumors105.  P70S6K1 is overactivated in the majority 
of human papillary cancer cells106, small cell lung cancer cells107 and pancreatic cancer 
cells108.  P70S6K1 is implicated in playing an important role in PTEN negative and in 
AKT-overexpressing tumors109,110.  PTEN+/- mice show increased incidence of uterine 
and adrenal medullary tumors.  PTEN levels are decreased and S6K is activated in 
these tumors.  Treatment of mice with the rapamycin analog CCI-779 causes a 
reduction in p70S6K1 activation and inhibits tumor growth 110.   Human tumor cell 
lines lacking PTEN showed an increase of phosphorylated S6 and total S6 when 
compared to PTEN wild-type cells109.  Tumor formation by PTEN-negative or by 
AKT-overexpressing human cancer cells in SCID mice is inhibited by CCI-779.  These 
findings suggest that the activity of p70S6K1 is correlated with PI3K-induced 
tumorigenesis.  
The pharmacological agent rapamycin can block the activation of p70S6K1.  
Rapamycin binds the immunophilin, FK-506-binding protein 12111, and this complex 
inhibits the cellular target of rapamycin, mTOR/RAFT/FRAP112.  The complex inhibits 
the function of mTOR, blocking growth factor induced activation of p70S6K1103 and 
phosphorylation of the suppressor of the eukaryotic initiation factor 4E (eIF-4E)113.  
This results in the specific inhibition of translation of transcripts encoding ribosomal 
proteins, and several proteins essential for cell cycle progression such as cyclin D1114 
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and p21115.  
The PI3K-p70S6K1 signaling pathway is required for VEGF-mediated 
proliferation of endothelial cells 116.  P70S6K1-mediated protein synthesis is a critical 
step for vascular endothelial cell proliferation.  Selective inhibition of p70S6K1 with 
rapamycin inhibited VEGF stimulated HUVEC proliferation117.  Rapamycin inhibits 
primary and metastatic tumor growth by inhibiting angiogenesis in vivo 118.  
Rapamycin also effectively controlled the growth of established tumors. Rapamycin 
showed antiangiogenic activities linked to a decrease in the production of VEGF in vitro.  
Hypoxia increases sprout formation in rat and mouse 3-dimensional models of 
angiogenesis via a rapamycin-sensitive mechanism119. 
Loss of PTEN and the gain-of-function of PI3K signaling render HIF-1α 
induction pathway sensitive to rapamycin.  Rapamycin inhibits both stabilization of 
HIF-1α and transcriptional activity of HIF-1 in hypoxic cancer cells69.  The inhibitory 
effect of rapamycin on HIF-1-dependent transcription in PC-3 cells is mediated through 
the suppression of mTOR function.  Rapamycin interferes with HIF-1 activation in 
hypoxic cells by increasing the rate of HIF-1α degradation120.  
 
V. Survivin and PI3K/AKT pathway 
The evasion from apoptosis during homeostasis is thought to be a critical step 
for tumorigenesis.  The inhibitor of apoptosis (IAP), including ML-IAP, XIAP, cIAP1, 
cIAP2, NIAP, apollon and survivin, is mainly involved in antiapoptosis.  This family 
of proteins are characterized by a signature domain of about 70 amino acids (aa) termed 
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baculovirus IAP repeat (BIR)76,121-125, which is evolutionarily conserved including virus, 
yeast, nematode, fly, and mammalian.  Survivin, a unique member in the IAP family, is 
expressed primarily in fetal but not adult tissues, but it is highly expressed in cancer126.  
Survivin is cell cycle regulated, and involved in both control of apoptosis and regulation 
of cell division. The anti-apoptotic function of survivin results from its binding to the 
mitotic spindle during G2/M in transformed cells, probably in a complex with cdk4 and 
p21 which blocks caspase-3 activation127. 
Non-cell-cycle-dependent mechanisms influencing survivin expression involve 
responses to hematopoietic and vascular remodeling cytokines, STAT3-dependent 
signaling and PI3K activity128. The upregulation of survivin induced by 
granulocyte-macrophage colony stimulating factor (GM-CSF), angiopoietin-1 (Ang-1) 
and VEGF is accompanied by the activation of PI3K/AKT.  PI3K inhibitor LY294002 
inhibited survivin expression on GM-CSF stimulation of acute myeloid leukemia cells 
129
.  Angiopoietin-1 acting via the Tie 2 receptor induces phosphorylation of the AKT, 
which is associated with up-regulation of survivin in endothelial cells 130.  VEGF 
up-regulates survivin via the PI3K/AKT signaling pathway in human neuroblastoma 
cells131.  VEGF leads to the induction of the survivin protein in human umbilical vein 
endothelial cells132.    Survivin plays a pivotal role in VEGF-mediated endothelial cell 
protection by preserving the microtubule network133.  The activation and regulation of 
survivin was induced by hypoxic preconditioning during human coronary arteriolar 
endothelial cells survival and tubular morphogenesis134.  They showed the involvement 
of NF-κB and PI3-kinase as essential components of survivin expression. 
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ABSTRACT 
 
Ovarian cancer is the leading cause of death from gynecological malignancy for 
women.  The amplification of the PI3K catalytic subunit (p110α) and the lost function 
of PTEN are frequently detected in ovarian cancer cells.  PI3K plays an important role 
in tumorigenesis.  To specifically inhibit PI3K activity in ovarian cancer cells, we 
constructed small interfering RNA (siRNA) against p110α.  The expression of p110α 
siRNA significantly decreased cell migration, invasion, and proliferation compared to the 
siSCR control cells.  The expression of p110α siRNA induced CDK inhibitor p27KIP1 
levels, while it decreased levels of cyclin D1, CDK4, and phosphorylated retinoblastoma 
protein.  PI3K transmits the mytogenic signal through AKT.  AKT has three isoforms 
in the cells:  AKT1, AKT2 and AKT3.  We found that inhibition of AKT1 is sufficient 
to affect cell migration, invasion, and proliferation.  Expression of AKT1 siRNA had a 
similar effect as p110α siRNA in the cells.  We showed the roles of specific PI3K and 
AKT isoforms in the cells, which are important to understanding the mechanism of 
PI3K/AKT signaling in ovarian cancer cells.  Both p110α and AKT1 siRNA-expressing 
cells decreased the activation of p70S6K1.  Inhibition of p70S6K1 activity by its siRNA 
also decreased cell migration, invasion, and proliferation associated with the induction of 
p27KIP1 levels, and with the inhibition of cell cycle-associated proteins including cyclin 
D1, CDK2, and phosphorylated retinoblastoma protein.  This study demonstrates the 
important role of the PI3K/AKT/mTOR/p70S6K1 pathway in cell proliferation, 
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migration, and invasion in ovarian cancer cells by using siRNA-mediated gene silencing 
as a reverse genetic method. 
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INTRODUCTION 
 
Of the gynecological malignancies affecting women in Western countries, ovarian 
cancer has the highest mortality rate and is among the most common of female 
malignancies 1.  Ovarian cancer poses many treatment difficulties.  The cancer is often 
undetectable in its early stages, and therefore diagnosis usually occurs when surgical 
treatment is no longer an effective option.  Moreover, ovarian cancer cells are known to 
develop resistance to chemotherapeutic treatments, resulting in a dramatic decrease in the 
overall survival rate, with a significant decrease to 30% for patients in advanced stages 2.  
Recent genetic studies have shown that ovarian cancer contains frequent mutations in 
phosphatidylinositol 3-kinase (PI3K) and phosphatase and tensin homologue (PTEN)3.  
PIK3CA (the gene encoding the p110α catalytic subunit of PI3K) is frequently increased 
in copy number in 40% of ovarian cancer cell lines and patient tumor samples 4.  
PIK3CA has somatic mutations in several other cancers, including 32% of colorectal 
cancers, 27% of glioblastomas, 25% of gastric cancers 5.  PTEN is mutated in a subset 
of late-stage ovarian cancer patient samples and decreased PTEN expression 
accompanies the progression of ovarian cancer 6.  Furthermore, mutations of the PTEN 
tumor-suppressor gene are frequently detected in many human cancers 3,7,8.   
PI3K are heterodimers comprised of a regulatory and a catalytic subunit 9.  PI3K 
catalyzes the phosphorylation of phosphatidylinositol-containing lipids at their 3-position.  
Receptor tyrosine kinases activate PI3K 10, and this activation has been implicated in 
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several human cancers 11.  Cellular functions such as proliferation, differentiation, 
anti-apoptosis, tumorigenesis and angiogenesis have been linked to PI3K activity 12.  We 
recently found that PI3K expression mediated cell differentiation and angiogenesis 13-15. 
Therefore, understanding the precise role of PI3K in ovarian cancer would provide a 
successful approach for treating human ovarian cancer.  PTEN is a lipid phosphatase 
that functions as an antagonist to PI3K through specific activity to remove phosphate 
from the D3 position of the inositol ring 16.  Thus, inhibition of PI3K or molecules 
involved in the PI3K signaling pathway would provide the potential for cancer treatment.  
LY294002 and wortmannin are two widely used PI3K inhibitors that inhibit its catalytic 
activity.  The PI3K inhibitor LY294002 has been shown to inhibit ovarian cancer cell 
proliferation in vitro and to decrease ovarian cancer growth and ascites formation in mice 
inoculated with OVCAR-3 cells in vivo 17.  LY294002 also has been proven to increase 
the efficacy of the chemotherapeutic agent paclitaxel 18.  However, there are three major 
classes of PI3K isoforms existing in the cells 19 and LY294002 has a broad inhibitory 
effect against all the PI3K catalytic isoforms as well as other kinases such as ATM and 
ATR.  Thus, in this study we want to specifically inhibit the p110α subunit of PI3K by 
small interference RNA (siRNA). 
siRNA is a post-transcriptional gene-silencing mechanism induced by 
double-stranded RNA homologous to the sequence of the target gene 18,20, and contains 
small 21-23-nt dsRNAs that mediate post-transcriptional gene-silencing 21.  Introduction 
of chemically synthesized siRNAs can induce gene silencing in mammalian cells.  
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Transfection of short 21-nt RNA duplexes into mammalian cells interferes with gene 
expression and does not induce the unspecific anti-viral response 22.  Chemically 
synthesized siRNA usually induce only a transient reduction of endogenously expressed 
target mRNA.  Recently, a number of groups have developed siRNA-based expression 
systems to establish stably transfected mammalian cell lines expressing functional siRNA 
molecules 23-25.  The stable cell lines can be used to study the loss-of-function 
phenotypes.  The potential of using siRNA technology to “knock down” the expression 
of any gene in mammalian cells is set to revolutionize the ability of reverse genetics to 
assess the function of a gene.   
The precise function of the PI3K pathway in ovarian cancer progression has not 
been fully studied.  In this study, we wanted to determine the function of the p110α 
subunit in ovarian cancer.  We used a vector-based siRNA expression system to 
knockdown the expression of p110α in ovarian cancer cells.  To investigate the role of 
p110α siRNA (siP2) in ovarian cancer progression, we performed cell migration, invasion, 
and proliferation assays using cells expressing siRNA against the p110α subunit.         
An important downstream target of PI3K is the serine-threonine kinase AKT 26.  AKT 
has three different isoforms:  AKT1, AKT2 and AKT3 which share a high degree of 
structural similarity 27.  AKT1 kinase activity is frequently elevated in ovarian cancer 28, 
and this results in high levels of AKT phosphorylation and activity.  Deregulation of 
AKT kinase activity has been implicated in the regulation of tumor cell survival, 
resistance to apoptosis, cell proliferation, and growth 11.  AKT2 amplification was found 
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in ovarian carcinomas 29.  The specific role of each AKT isoform in ovarian tumor 
formation is unknown.  We hypothesize that AKT1 plays an important role in ovarian 
cancer cells.  To determine the role of the AKT1 isoform in ovarian cancer cells, we 
inhibited AKT1 using siRNA specific to AKT1, and analyzed how siRNA expression 
affects migration, invasion, and proliferation.  Because AKT has been shown to 
phosphorylate p70S6K1 30, we will also study ovarian cancer progression using siRNA 
against p70S6K1.  
The 70KDa ribosomal S6 kinase p70S6K1 is known to regulate cell growth by 
inducing protein synthesis components 31.  p70S6K1 is activated through the PI3K 
pathway 32,33 and the MAPK pathway 34.  Gene encoding for p70S6K1 is also amplified 
in ovarian cancer cells 35, and its p70S6K1 kinase is constitutively phosphorylated in 
ovarian cancer cells.  We hypothesize that PI3K/AKT may regulate cell migration, 
invasion, and proliferation through p70S6K1.  Thus, we determined whether inhibition 
of PI3K and AKT by siRNA affected p70S6K1 activation, and whether siRNA against 
p70S6K1 has similar inhibitory effects as siRNA against PI3K/AKT. 
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MATERIALS AND METHODS 
  
Reagents and Cell Culture 
Total RNA was isolated using the Trizol reagent from Invitrogen (Life Technology). 
The primers for the p110α, AKT1, AKT2 and GAPDH were from GenScript Corp. 
(Piscataway, NJ). The antibodies against p21, p27, CDC25A, CDK2, CDK4, cyclin E, 
PCNA, AKT1 and AKT2 were from Santa Cruz Biotechnology (Santa Cruz, CA) and the 
antibodies against Rb, phospho-Rb (Ser780, Ser795, or Ser807/811), Rb C-terminal, 
cyclin D1, p70S6K1, and phospho-p70S6K1 (Thr421/Ser424) were from Cell Signaling 
Technology (Beverly, MA).  The antibody against β-actin was from Sigma (St. Louis, 
MO).  The horseradish peroxidase (HRP)-conjugated anti-rabbit IgG and anti-mouse 
IgG were from Perkin Elmer Life Sciences (Boston, MA).  The human ovarian cancer 
cell line OVCAR-3 (American Type Culture Collection, Manassas, VA) was maintained 
in RPMI 1640 (GIBCO BRL, Grand Island, NY) supplemented with 10% FBS, 2 mM 
L-glutamine, and 0.2% insulin, 100 U/ml penicillin, and 100 µg/ml streptomycin, and 
cultured at 37°C in 5% CO2 incubator.  Trypsin (0.25%)/EDTA solution was used to 
detach the cells from the culture plate for passing the cells. 
 
siRNA and Plasmid Constructs 
The oligonucleotides encoding 19-mer hairpin sequences specific to the p110α, 
AKT1, and p70S6K1 were designed using siRNA converter software.  The sequence of 
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small interfering RNA construct targeted to p110α, AKT1 and p70S6K1 were as follows: 
p110α, sense strand, AGTTCCCAGATATGTCAGTuu, and antisense strand, 
ACTGACATATCTGGGAACTuu; AKT1, sense strand, 
GAAGGAAGTCATCGTGGCCuu, and antisense strand, 
GGCCACGATGACTTCCTTCuu; p70S6K1, sense strand, 
GUUCAAGCUCAUCCAUUCUuu, and antisense strand, siRNA 
AGAAUGGAUGAGCUUGAACuu. A scramble siRNA with the same nucleotide 
composition as the siRNA but which lacks significant sequence homology to the genome 
was also designed. The oligonucleotides were synthesized, annealed, and ligated into the 
linearized pSilencer 2.0-U6 vector (Ambion, Austin, TX).  The plasmids that express 
siRNA against p110α, AKT1, and p70S6K1 were named as siP2, siA1 and sip70S6K1. 
The scramble siRNA was named as siSCR. 
 
Selecting a population of cells that stably express siRNA 
OVCAR-3 cells were plated into 6 well plates. 2µg of siP2, siA1, sip70S6K or 
siSCR was transfected into OVCAR-3 cells using Lipofectamine (Invitrogen) and 
cultured for 24h without antibiotic selection. Then the cells were cultured in medium 
containing 500µg/ml G418 (Sigma) until all of the cells in the non-transfected control 
culture were killed. The antibiotic-resistant cells were pooled and passaged in medium 
containing 250µg/ml G418 as needed. 
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Semi-Quantitative RT-PCR  
Total RNA was isolated from 1 x 106 cultured cells with Trizol reagent (Invitrogen). 
First-strand cDNA was synthesized from 1 µg of total RNA using AMV Reverse 
Transcriptase, an oligo(dT) primer and dNTP(Promega). Primers used for amplification 
and internal probes for hybridization were as follows: PIK3CA forward, 
5’-TATGGTTGTCTGTCAATCGGTGA-3’; PIK3CA reverse, 
5’-GCCTTTGCAGTGAATTTGCAT-3’; AKT1 forward, 
5’-ATGAGCGACGTGGCTATTGTGAAG-3’; AKT1 reverse, 
5’-GAGGCCGTCAGCCACAGTCTGGATG-3’; AKT2 forward, 
5’-ATGAATGAGGTGTCTGTCATCAAAGAAGGC-3’; AKT2 reverse, 5’- 
TGCTTGAGGCTGTTGGCGACC-3’; GAPDH forward, 
5’-CCACCCATGGCAAATTCCATGGCA-3’; GAPDH reverse 
5’-TCTAGACGGCAGGTCAGGTCCACC-3’. Each RT-PCR reaction consisted of 32 
cycles of 1 min at 94°C, 1 min at 55°C and 1 min at 72°C. Quantitation of the amount of 
PCR product was performed after electrophoresis on 2% agarose gels and ethidium 
bromide staining. 
 
Wound-Healing Assays 
OVCAR-3 cells expressing siRNA or siSCR were cultured to 100% confluence.  
The wound-healing assays were performed using a sterile 200 µl pipette tip to scratch the 
cells to form a wound.  The cells were then cultured in 10% FBS medium for 24 h, and 
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then fixed with formalin.  Migration of wounded cells was evaluated at 0 and 24 h with 
an inverted Olympus phase-contrast microscope.  
 
Cell Migration Assays 
The migration assay was conducted by the transwell assay.  The cells were split at a 
ratio of 1:2 the day before the assay.  The transwells were coated with collagen at a 
concentration of 20 µg/ml in 1x PBS.  The top chambers of the transwells were added 
with 0.2 ml of cells (5x 105 cells/ml) in serum-free medium, and the bottom chambers 
were added with 0.25 ml of RPMI 1640 medium containing 10% FBS.  The cells were 
incubated in the transwells at 37°C in 5% CO2 for 24 h.  Migrated cells were fixed and 
stained with hematoxylin.  The migrated cells in each well were counted in three 
different fields per experiment under the microscope.  The mean values were obtained 
from three replicate experiments and were subjected to the t-test. 
 
Cell Invasion Assays 
OVCAR-3 cells were cultured to near confluence in RPMI 1640 medium containing 
10% FBS.  The cells were harvested by trypsinization and washed in RPMI medium 
without serum.  The cells were suspended in RPMI 1640 medium at 5x 105 cells /ml.  
Prior to preparing the cell suspension, the dried layer of matrigel matrix was rehydrated 
with serum-free RPMI 1640 medium for 2 h at 37°C.  The rehydration solution was 
carefully removed, 0.75 ml RPMI 1640 medium containing 10% FBS was added to each 
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well as a chemoattractant, and 0.5 ml (2.5x 105 cells) of cell suspension was added to 
each well.  The plates were incubated for 48 h at 37°C.  The invaded cells on the 
bottom surface of the membrane were fixed and stained by sequentially transferring them 
through wells of a second 24-well plate containing the three solutions from the 
Diff-Quik® staining kit (Dade Behring Inc.).  The cells were enumerated by taking 
photomicrographs at 200x magnification.  The cells in three different fields of each well 
were counted with two wells per treatment.  The mean values were obtained from three 
replicate experiments and were subjected to the t-test.  
 
Cell Proliferation Assays 
Cells were seeded in 12-well plates at a density of 2x 105 cells/well in RPMI 1640 
medium supplemented with 10% FBS at 37°C in 5% CO2 incubator for 24 h, 48 h, and 72 
h.  Cells were scraped and washed twice with PBS and centrifuged at 1,000 rpm for 5 
min.  Cells were resuspended in 1 ml of Hanks' balanced salt solution and counted.  The 
total cell number was normalized to that in the control at 0 h.  All samples were assayed 
in triplicate.  The proliferation assays were performed three times. 
 
Immunoblotting Analysis 
Cells were cultured in a 60 mm dish at a density of 5× 105 cells/dish in RPMI 1640 
medium with 10% FBS for 24 h at 37°C in 5% CO2 incubator.  Cells were harvested and 
lysed on ice for 30 min in RIPA buffer [150 mM NaCl, 100 mM Tris (pH 8.0), 1% Triton 
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X-100, 1% deoxycholic acid, 0.1% SDS, 5 mM EDTA, and 10 mM NaF], supplemented 
with 1 mM sodium vanadate, 2 mM leupeptin, 2 mM aprotinin, 1 mM 
phenylmethylsulfonylfluoride, 1 mM dithiothreitol, and 2 mM pepstatin A.  After 
centrifugation at 12,000 rpm for 15 min, the supernatant was harvested as the total 
cellular protein extract.  The protein concentrations were determined using Bio-Rad 
protein assay reagent (Richmond, CA).  The total cellular protein extracts were separated 
by SDS-PAGE and transferred to nitrocellulose membrane.  Membranes were blocked 
with 5% nonfat dry milk in PBS containing 0.05% Tween 20 and incubated with 
antibodies against p27, p21, CDK4, cyclin D1, Rb C-terminal, phospho-Rb (Ser780), 
phospho-Rb (Ser795), phospho-Rb (Ser807/811), p70S6K1, phospho-p70S6K1 
(Thr421/Ser424), p110α, AKT1, AKT2 and β-actin.  Blots were washed three times in 
PBS buffer, followed by incubation with the appropriate HRP-linked secondary 
antibodies.  The specific proteins in the blots were visualized using the enhanced 
chemiluminescence reagent (NEN, Boston, MA).  The experiments were carried out on 
three separate occasions.  
 
Statistical analysis 
The data represent the mean ±SD from three independent experiments.  Statistical 
analysis was performed by Student’s t test at a significance level of P <0.05.  
 
 
 45
RESULTS 
 
Expression of siRNA against p110a Catalytic Subunit of PI3K (siP2) Inhibited Ovarian 
Cancer Cell Migration and Invasion 
Cell migration is a key cellular feature of tumor progression because it regulates 
metastasis.  Both tumor cell migration and invasion through the basement membranes 
are crucial steps in the multistage process that leads to metastasis36.  To determine the 
function of the p110α subunit of PI3K in ovarian cancer cell migration, we used 
OVCAR-3 cells that express p110α in high copy number.  We showed that p110α 
mRNA level and protein level were decreased in siP2 expression cells when compared to 
p110α mRNA level and protein level in siSCR control cells (Fig. 1A).  To determine if 
the siP2 expression can inhibit cell motility, we performed wound-healing experiments 
and measured the distance of cell migration to the wound area (Fig. 1B).  Our results 
showed that the cells expressing siP2 had a 4-fold decrease in wound-healing rate in 24 h 
when compared to the siSCR control cells (Fig. 1C).  We also analyzed cell migration 
using transwell assays to test the migration ability of cells expressing siP2.  Similar 
results were obtained in the cells expressing siP2, which had a 4.2-fold decrease (p < 0.05) 
when compared to those expressing siSCR alone (Fig. 1D and 1E).   
Cancer cells need to cross the basement membranes when they initially invade the 
lymphatic or vascular beds during dissemination.  The invasion process is comprised of 
distinct events which include the attachment of cells to the basement membrane, 
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secretion of enzymes which degrade the basement membrane, and the migration of cells 
into the target tissue in response to specific chemotactic stimuli 37.  To study whether 
p110α plays an important role in cell invasion, we used the invasion chamber to measure 
the number of invasive cells migrating through matrigel, a solid gel of in vitro basement 
membrane.  The matrigel layer contains the membrane and pores, blocking noninvasive 
cells from migrating through.  We analyzed the number of invasive cells expressing the 
siP2 or siSCR alone.  The results demonstrated that siP2-expressing cells had a cell 
invasion rate of 10-fold less than those expressing siSCR alone (p < 0.05) (Fig. 2).  
These data showed that PI3K inhibition by siP2 expression in ovarian cancer cells 
inhibits cell invasion.  
 
SiP2 Decreased Cell Proliferation and Inhibited Cell Cycle-Associated Proteins Through 
p27Kip1 Induction 
Because PI3K is a key regulatory protein that is known to stimulate cell growth, we 
examined proliferation in cells in which the p110α subunit had been silenced by siRNA.  
OVCAR-3 cells expressing siP2 or siSCR control were seeded and cultured.  Total cell 
numbers were counted 24 h, 48 h, and 72 h after the incubation.  As shown in Fig. 3A, 
the cells expressing siSCR grew very quickly during the 72 h in culture, while the cells 
expressing siP2 had a much slower proliferation rate.  The results indicated that p110α 
plays an important role in the proliferation of ovarian cancer cells.  To study cell 
proliferation in further detail, we then examined cell cycle regulatory proteins involved in 
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cell cycle control.  OVCAR-3 cells expressing siP2 or siSCR were cultured.  Total 
proteins were analyzed by immunoblotting assay.  We found that levels of cyclin D1, 
CDK4, cyclin E, CDK2, p21 and phosphorylated Rb were inhibited by siP2, and that the 
level of p27 was induced by siP2 when compared to siSCR control (Fig. 3B).  The 
levels of PCNA, CDC25A and β-actin remained unchanged.  These results suggest that 
inhibition of PI3K may inhibit cell cycle-associated proteins through the induction of 
CDK inhibitor p27.  These data are consistent with our recent study indicating that G1 
cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT 
signaling in ovarian cancer cells 38.   
 
SiRNA Against AKT1 (siA1) Expression Inhibited the Migration and Invasion of Ovarian 
Cancer Cells 
AKT is a major downstream target of PI3K.  We showed that activation of AKT in 
ovarian cancer cells was inhibited by expression of siP2 (Fig. 4A).  AKT has three 
different isoforms:  AKT1, AKT2, and AKT3.  The precise role of each AKT isoform 
in cancer cells is still unknown.  To determine the role of AKT1 in ovarian cancer cell 
migration, we generated a stable cell line expressing siRNA specific to AKT1.  We 
tested the effect of siA1 construct on the expression of AKT1 mRNA by RT-PCR.  We 
showed that AKT1 mRNA level was decreased by the expression of siA1 in ovarian 
cancer cells and AKT2 mRNA level was unchanged in ovarian cancer cells expressing 
siA1 (Fig.4B).  Western Blot results showed that AKT1 protein level was decreased by 
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the expression of siA1 and AKT2 protein level was unchanged in ovarian cancer cells 
expressing siA1 (Fig.4B).  A wound-healing assay was carried out to test the cell 
migration and proliferation of cells expressing siA1.  The cells expressing siA1 had a 
much slower wound-healing rate when compared to siSCR control (Fig. 4C and 4D).  
To further determine the effect of siA1 expression on cell migration, the cell migration 
was analyzed by transwell assays.  The cells expressing siA1 had a cell migration rate of 
5-fold less than those expressing siSCR control (Fig. 4E and 4F).  To study whether 
AKT1 affects cell invasion, we determined if siA1 expression would inhibit cell invasion 
by testing its ability to penetrate the matrigel.  The cells expressing siA1 had a cell 
invasion rate of 2.7-fold less than those expressing siSCR (Fig. 5A and 5B).  These 
results demonstrate that AKT1 is required for both cell migration and invasion in ovarian 
cancer cells.  
 
AKT1 Mediates Cell Proliferation and Cell Cycle Progression Induced by PI3K 
To investigate if AKT1 is involved in ovarian cancer cell proliferation, we examined 
proliferation in cells in which AKT1 had been silenced by siRNA.  OVCAR-3 cells 
expressing siA1 or siSCR were seeded and cultured.  Total cell numbers were counted 
24 h, 48 h, and 72 h after the incubation.  As shown in Fig. 6A, the cells expressing 
siSCR multiplied much more quickly than the cells expressing siA1 (p < 0.05).  The 
results indicate that AKT1 plays an important role in ovarian cancer cell proliferation. To 
investigate whether the inhibition of AKT1 affects cell cycle-associated protein 
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expression, total cellular proteins were prepared and subjected to an immunoblot assay.  
As shown in Fig. 6B, the levels of cyclin D1, CDK4, CDK2, cyclin E, phospho-Rb 
(Ser780, Ser795 and Ser807/811), and CDK inhibitor p21 were decreased in OVCAR-3 
cells expressing siA1, whereas the level of CDK inhibitor p27 was induced and the levels 
of PCNA, CDC25A and β-actin remained unchanged.  These results suggest that AKT1 
may mediate cell cycle progression through the expression of cyclins and CDKs. 
 
p70S6K1 is A Potential Downstream Target of PI3K and AKT in Cell Migration and 
Invasion 
To test whether p70S6K1 is a downstream target of PI3K and AKT, we showed that 
phosphorylated p70S6K1 was decreased in ovarian cancer cells expressing siP2 or siA1 
(Fig. 7A).  To investigate if p70S6K1 is required for ovarian cancer cell migration and 
invasion, we designed siRNA specific to p70S6K1 (sip70S6K1).  The OVCAR-3 cells 
were transfected with sip70S6K1 construct and then selected with G418.  After the 
selection, we established a stable cell line expressing sip70S6K1.  The cells expressing 
sip70S6K1 or siSCR were analyzed for p70S6K1 expression and activation by an 
immunoblotting assay.  Total p70S6K1 and phosphorylated p70S6K1 proteins were 
reduced in cells expressing sip70S6K1 (Fig. 7B).  Phospho-S6 ribosomal protein, the 
physiological substrate of p70S6K1, was also reduced in the cells expressing sip70S6K1 
plasmid (Fig. 7B).  Thus, this result indicates that sip70S6K1 expression inhibits 
p70S6K1 expression/function.  To determine the role of p70S6K1 in ovarian cancer cell 
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migration, transwell assays were performed.  The cells expressing sip70S6K1 had a cell 
migration rate of 7-fold less than those expressing siSCR (p < 0.05) (Fig. 8A and 8B).  
To test if p70S6K1 is required for cell invasion, cell invasion assays were performed.  
The cells expressing siRNA specific to p70S6K1 had an invasion rate of 4-fold less than 
those expressing siSCR (p < 0.05) (Fig. 8C and 8D).  Taken together, these data 
demonstrate that p70S6K1 downstream of PI3K/AKT is required for ovarian cancer cell 
migration and invasion.                                   
 
sip70S6K1 Expression Decreased Cell Proliferation Associated with the Decrease of Cell 
Cycle-Associated Protein Expression 
To investigate if p70S6K1 can regulate ovarian cancer cell proliferation, we 
specifically inhibited p70S6K1 activity using the siRNA.  OVCAR-3 cells expressing 
sip70S6K1 or siSCR were seeded and cultured.  As shown in Fig. 9A, cells expressing 
siSCR proliferated much more quickly than the cells expressing sip70S6K1.   
To study whether p70S6K1 regulates cell proliferation through the expression of 
proteins, OVCAR-3 cells expressing sip70S6K1 or siSCR were analyzed for the 
expression of cell cycle-associated protein expression.  We found that levels of cyclin 
D1, CDK4, cyclin E, and phosphorylated Rb were lower in the OVCAR-3 cells 
expressing p70S6K1 (p < 0.05).  The level of p27 was higher in OVCAR-3 cells 
expressing sip70S6K1 when compared with the cells expressing siSCR (p < 0.05) (Fig. 
9B).  The levels of CDC25A and β-actin were not changed.  These results indicate that 
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p70S6K1 is required for cell cycle progression.  The induction of CDK inhibitor p27 
may be a negative regulator for the expression of cyclins and CDKs in the ovarian cancer 
cells.  
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DISCUSSION 
           
Ovarian cancer has the worst prognosis of any gynecological disease; it is one of the 
most difficult cancers to detect and to treat1.  The current major research focus is 
identifying an effective therapeutic treatment.  PI3K has many cellular functions in 
response to growth factors and therefore an understanding of PI3K has the potential to 
lead to a treatment for ovarian cancer.  Recent studies indicate that PIK3CA, the gene 
encoding the p110α catalytic subunit of PI3K, is increased in copy number in primary 
ovarian cancer cells and several ovarian carcinoma cell lines 4.  Moreover, mutation of 
AKT, an important downstream target of PI3K, is frequently detected in ovarian cancer 39.  
PI3K inhibitors could potentially provide useful information about the role of the 
PI3K/AKT pathway in human cancers; however, the most commonly used PI3K 
inhibitors, LY294002 and wortmannin, have broad inhibitory activity against all the p110 
isoforms.  Therefore, in this study we used the siRNA technique to inhibit specific 
isoforms of PI3K and AKT in ovarian cancer cells, and determined their effects on cell 
migration, invasion and proliferation.  Our study demonstrates that inhibition of the 
p110α subunit by siRNA resulted in decreased cell migration, invasion and proliferation 
in ovarian cancer cells.   
Cell migration is a fundamental aspect of cancer cell growth 36, and is a complex 
process that requires the high coordination of actin polymerization, formation, release of 
focal adhesions, and myosin motor activity 37.  Cell migration requires cell invasion, the 
 53
process of cellular-induced degradation of the basal membrane through membrane 
penetration.  Ovarian cancer is a highly metastatic cancer, and therefore cell migration 
and invasion are particularly important processes of ovarian cancer progression 40.  
Investigation of the PI3K signaling pathway in cell migration and invasion will enable us 
to understand ovarian cancer progression.  An important finding in this study is that the 
inhibition of p110α by siRNA significantly decreased the rate of cell migration and 
invasion in ovarian cancer cells. Cell migration may be affected by the rate of cell 
proliferation. In our study, we found that cells expressing siP2 had a 1-fold decrease in 
cell proliferation rate in 48 h when compared to the siSCR control cells.  However, 
siP2-expressing cells had a cell migration rate of 4.2 fold less than those expressing 
siSCR and cell invasion rate of 10-fold less than those expressing siSCR. It suggests cell 
proliferation may not play a major role on cell migration and invasion in this study. This 
demonstrates that the p110α subunit affects multiple cell functions, and also reveals the 
major functions of the PI3K isoforms in ovarian cancer cells.  
PI3K activation is required for cancer progression because it promotes tumor growth, 
including cell proliferation and cell cycle progression.  In ovarian cancer specifically, 
the PI3K pathway has been implicated in cell proliferation and G1 cell cycle progression 
38
. In this study, we have shown that siRNA-inhibited p110α expression decreased cell 
proliferation, which demonstrates that inhibition of p110α can affect tumor cell growth.  
One cause of tumorigenesis is uncontrolled cell division.  The cell cycle is regulated by 
the coordinated action of cyclin-dependent kinase (CDK) complexes and CDK inhibitors 
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(CKIs) 41.  Therefore, we wanted to prove that inhibition of p110α could also affect 
proliferation through signals to the cell cycle machinery.  Our results showed that siP2 
expression in ovarian cancer cells inhibited levels of cyclin D1, CDK4, cyclin E, p21 and 
phosphorylated Rb, and that it induced the level of p27KIP1.  Since p27KIP1 is known to 
inhibit CDKs, our results demonstrate that siP2 may decrease cell proliferation and 
inhibit cell cycle-associated proteins specifically through the induction of p27KIP1 in 
ovarian cancer cells, thereby disrupting the regulation of G0/G1 cell cycle transition 
necessary for tumor growth.  These results also suggest that p110α subunit expression in 
ovarian cancer cells inhibits p27KIP1, thereby inducing proliferation and increased cell 
cycle progression.    
AKT is composed of three isoforms (AKT1, AKT2, and AKT3) and although all 
isoforms may be expressed, only certain isoforms may be active in a particular cell type. 
We hypothesize that AKT1 is the most prominent of the three in cellular functions.  To 
determine the function of AKT1 isoform in ovarian cancer progression, we used siRNA 
against AKT1 and studied the role of siA1 cells in wound-healing and cell migration and 
invasion in ovarian cancer cells.  Our results showed that siA1 expression in ovarian 
cancer cells significantly decreased the wound-healing rate as well as cell migration and 
invasion, demonstrating that AKT1 is the major AKT isoform for cellular migration and 
invasion in ovarian cancer.  This result correlates with the inhibition of cell migration 
and invasion in siP2-expressing cells.  Concomitantly, expression of siA1 inhibited the 
cell proliferation rate, decreased expression of cyclin D1, CDK4, cyclin E, p21 and 
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phosphorylated Rb, and induced the expression level of p27 Kip1 in ovarian cancer cells.  
This indicates that expression of siA1 can inhibit cell proliferation through regulation of 
cell cycle-associated proteins.  These results also show that PI3K signaling can transmit 
through AKT1, and that PI3K induces AKT activation in ovarian cancer cells.  
Research has demonstrated that the PI3K/AKT pathway induces p70S6K1, which is 
known to regulate cell growth by inducing protein synthesis components.  Therefore, we 
wanted to determine whether p70S6K1 plays a role in ovarian cancer cell migration, 
invasion, and proliferation.  Earlier data has shown that siP2 and siA1 expression can 
affect p70S6K1 expression.  In this study, the results show that expression of siRNA 
specific to p70S6K1 in ovarian cancer cells can decrease cell migration and invasion 
rates, and that this decrease correlates with the inhibition of cell migration and invasion 
in p110α knockdown cells.  Furthermore, inhibition of p70S6K1 in ovarian cancer cells 
decreased cell proliferation and altered cell cycle-associated proteins.  As in the 
experiments using siP2 and siA1, siRNA against p70S6K1 expression decreased levels of 
cyclin D1, CDK4 and phosphorylated Rb, and induced levels of p27KIP1.  This 
demonstrates the significance of p70S6K1 in ovarian cancer cell proliferation. 
There are some interesting observations that other transformed cells demonstrate cell 
type-specific and selective contribution of PI3K, AKT, mTOR and p70S6K1 in the cell 
proliferation, migration and invasion in contrast to OVCAR-3 42-45. In our study, we find 
the components of PI3K/AKT/mTOR/p70S6K1 pathway are critical for OVCAR-3 cell 
proliferation, migration and invasion.  
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In summary, these results suggest that p110α and AKT1 isoforms are major 
molecules in ovarian cancer progression.  The data demonstrates that expression of 
these isoforms decreased levels of the natural CDK inhibitor p27KIP1, thereby 
contributing to cell proliferation.  We also have shown that p27KIP1is upregulated in the 
presence of siRNA against PI3K, AKT, and p70S6K1 and that this upregulation inhibits 
cyclin and CDK activity, resulting in ovarian tumor growth inhibition.  Moreover, this 
study proves that through the induced expression of siRNA the 
PI3K/AKT/mTOR/p70S6K1 pathway is a novel target for therapeutic intervention in 
ovarian cancer. 
 
 
 
 
 
 
 
 
 
 
 
 57
CONCLUSIONS 
 
The expression of p110α siRNA significantly decreased cell migration, invasion, 
and proliferation compared to the siSCR control cells.  Inhibition of AKT1 is sufficient 
to affect cell migration, invasion, and proliferation in ovarian cancer cells.  Inhibition of 
p70S6K1 activity by its siRNA also decreased cell migration, invasion, and proliferation 
associated with the induction of p27KIP1 levels.  PI3K/AKT/mTOR/p70S6K1 pathway is 
critical for OVCAR-3 cell proliferation, migration and invasion. 
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FIGURE LEGENDS 
 
Fig. 1.  SiP2 inhibited OVCAR-3 cell migration and wound-healing. (A) Cells 
expressing siP2 or siSCR plasmid were cultured at a density of 5×105 cells/dish in RPMI 
1640 medium with 10% FBS for 24 h at 37°C in 5% CO2 incubator.  The total RNA was 
prepared and first strand cDNA was synthesized using AMV and oligo(dT) primer. 
PIK3CA mRNA in OVCAR-3 cells expressing siP2 or siSCR was assayed by 
semiquantitative RT-PCR.  The PIK3CA mRNA level was compared with the signal 
from control GAPDH mRNA level.  10µl of PCR product of siSCR and siP2 was run on 
2% agrose gel.  A single graph from triplicate determinations showing identical results 
is shown.  The cells (5× 105 cells/ml) expressing siP2 or siSCR were cultured in normal 
medium and lysed, and 50µg of protein was analyzed by immunoblotting with the 
antibodies against p110α and β-actin. (B) OVCAR-3 cells stably expressing siP2 or 
siSCR alone were cultured to 100% confluence.  A sterile 200µl pipette tip was used to 
scratch the cells to form a wound.  The cells were then washed with 1x PBS and 
cultured in 10% FBS medium for 24 h and fixed with formalin.  Migration of the cells to 
the wound was visualized at 24 h with an inverted Olympus phase-contrast microscope.  
The representative fields were photographed.  (C) The healing rate was quantified with 
measurements of the gap size after the culture.  Three different areas in each assay were 
chosen to measure the distance of migrating cells to the origin of the wound.  The 
healing rate of cells expressing siP2 was normalized to that of siSCR control cells.  The 
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mean values and the standard error were obtained from three experiments.  (D) The 
migration assay was conducted by transwell assay.  The cells expressing siP2 or siSCR 
were split(1:2) the day before the assay.   Migrated cells were fixed and stained with 
hematoxylin.  The representative fields were photographed.  (E) The migrated cells in 
each well were counted in three different fields under the microscope.  The mean values 
and the standard error were obtained from three individual experiments (P<0.05, 
Student’s test). 
 
Fig. 2.  SiP2 decreased OVCAR-3 cell invasion.  (A) OVCAR-3 cells expressing siP2 
or siSCR were cultured to near confluence in RPMI 1640 medium containing 10% FBS. 
The invasion assay was carried out according to the invasion assay method described in 
Material and Methods.  The invaded cells were enumerated by taking photomicrographs 
at 200x magnification.  The representative fields were photographed.  (B) The cells in 
three different fields of each experiment were counted.  The mean values and the 
standard error were obtained from three independent experiments (P<0.05, n=3). 
 
Fig. 3.  SiP2 decreased OVCAR-3 cell proliferation.  (A) Cell proliferation was 
measured by counting cell number of OVCAR-3 cells expressing siRNA against p110α or 
siSCR.  OVCAR-3 cells expressing siP2 or siSCR control were seeded in a 12-well 
plate at a density of 2×105 cells/ ml in RPMI 1640 medium with 10% FBS for 24 h, 48 h, 
and 72 h.  Cells were harvested and counted using a hemocytometer.  The number of 
 68
total cells expressing siP2 was counted and normalized to the number obtained in the 
siSCR control at 0 h.  The data represented the mean and the standard error from three 
independent experiments.  * indicates that the normalized cell number was significantly 
decreased compared to the control at the same time point (P<0.05, Student’s test).  (B) 
SiP2 expression leads to a change of cell cycle regulatory proteins.  Cells were cultured 
in a 60mm dish at a density of 5×105 cells/dish in RPMI 1640 medium.  The total 
cellular protein extracts were prepared and aliquots of proteins were separated on 
SDS-PAGE, analyzed by immunoblotting with antibodies against phospho-Rb (Ser795, 
Ser780, and Ser807/811), Rb C-terminal control, cyclin D1, CDK4, CDK2, cyclin E, 
CDC25A, p27KIP1, p21, PCNA, and β-actin.  The experiments were carried out on three 
separate occasions.  The bands were quantified by scanning densitometry using 
Eagleeye software. The relative mean densitometry between siRNA and siSCR was 
calculated.  The mean ratio ±SD was plotted on the graph. 
 
Fig. 4.  SiRNA against AKT1 inhibited OVCAR-3 cell migration and wound-healing.  
(A) Cells expressing siP2 or siSCR plasmid were cultured in a 60 mm dish at a density of 
5×105 cells/dish in RPMI 1640 medium with 10% FBS for 24 h, followed by incubation 
with serum-free medium for 16 h.  Cells were switched to the medium in the presence or 
absence of 100 nM insulin for 1 h as indicated.  The total cellular protein extracts were 
prepared and subjected to immunoblot analysis using antibodies against phospho-AKT 
(Ser473) and β-actin.  (B) Cells expressing siA1 or siSCR plasmid were cultured at a 
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density of 5×105 cells/dish in RPMI 1640 medium with 10% FBS for 24 h.  RT-PCR 
analysis of AKT1 mRNA level and AKT2 mRNA level in OVCAR-3 cells expressing 
siA1 or siSCR was carried out as the method mentioned above.  A single graph from 
triplicate determinations showing identical results is shown.  The cells (5× 105 cells/ml) 
were cultured in normal medium and lysed, and 50µg of protein was analyzed by 
immunoblotting with the antibodies against AKT1, AKT2 and β-actin. (C) OVCAR-3 
cells expressing siA1 or siSCR were cultured to 100% confluence.  A sterile pipette tip 
was used to scratch the monolayer cells to form a wound.  The cells were then cultured 
in 10% FBS medium for 24 h and fixed with formalin.  The images were recorded using 
a microscope.  (D) The wound-healing rate was quantified with measurements of the 
gap size over time.  Three different areas in each assay were chosen to measure the 
distance of migrating cells.  The wound-healing rate of cells expressing siA1 was 
normalized to that of the siSCR control cells.  The mean values and the standard error 
were obtained from three individual experiments (P<0.05, Student’s test).  (E) The 
migration assay was conducted by transwell assay.  The cells were split (1:2) the day 
before the assay.  The cells were incubated in the transwells at 37°C in 5% CO2 for 24 h.  
Migrated cells were fixed and stained with hematoxylin.  (F) The migrated cells in each 
well were counted in three different fields under the microscope.  The mean values and 
the standard error were obtained from three independent experiments (P<0.05, Student’s 
test). 
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Fig. 5.  SiA1 decreased OVCAR-3 cell invasion.  (A) OVCAR-3 cells expressing siA1 
or siSCR were cultured to near confluence in RPMI 1640 medium containing 10% FBS.  
The invasion assay was carried out according to the method mentioned above.  The 
representative fields were photographed.  (B) The cells were enumerated by taking 
photographs at 200x magnification.  The experiments were repeated three times.  The 
cells in three different fields of each experiment were counted.  The mean values and the 
standard error were obtained from three independent experiments (P<0.05, Student’s 
test).  
 
Fig. 6.  SiA1 decreased OVCAR-3 cell proliferation.  (A) Cell proliferation was 
measured by counting the number of OVCAR-3 cells expressing siA1 or siSCR.  
OVCAR-3 cells expressing siA1 or siSCR were seeded in a 12-well plate at a density of 
2×105 cells/ml in RPMI 1640 medium with 10% FBS for 24 h, 48 h, and 72 h.  Cells 
were harvested and counted using a hemocytometer.  The number of total cells was 
counted and normalized to the number obtained in the siSCR control at 0 h.  The data 
represented the mean and the standard error from three independent experiments.  * 
indicates that the normalized cell number was significantly decreased when compared to 
the control at the same time point (P<0.05, Student’s test).  (B) SiA1 expression leads to 
a change of cell cycle regulatory proteins.  Cells expressing siA1 or siSCR plasmid were 
cultured in a 60 mm dish at a density of 5×105 cells/dish in RPMI 1640 medium.  The 
total cellular protein extracts were prepared and subjected to immunoblot analysis using 
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specific antibodies against phospho-Rb (Ser795, Ser780 and Ser807/811), Rb C-terminal 
protein, cyclin D1, CDK4, CDK2, cyclin E, CDC25A, p27KIP1, p21, PCNA, and β-actin. 
The experiments were carried out on three separate occasions.  The bands were 
quantified by scanning densitometry using Eagleeye software.  The relative mean 
densitometry between siRNA and siSCR was calculated.  The mean ratio ±SD was 
plotted on the graph.  
 
Fig. 7.  SiP2 and siA1 decreased p70S6K1 activation, and siRNA against p70S6K1 
(sip70S6K1) expression decreased the expression of p70S6K1 protein in OVCAR-3 cells.  
(A) Cells expressing siP2, siA1 or siSCR plasmid were cultured in a 60 mm dish at a 
density of 5×105 cells/dish in RPMI 1640 medium, followed by incubation with 
serum-free medium for 16 h.  Cells were switched to the medium in the presence or 
absence of 100 nM insulin for 1 h as indicated.  The total cellular protein extracts were 
prepared and subjected to immunoblot analysis using antibodies against 
phospho-p70S6K1 (Thr421/Ser424) and β-actin.  (B) Generation of cells stably 
expressing sip70S6K1.  The oligonucleotides encoding 19-mer hairpin sequences 
specific to the p70S6K1 mRNA were designed using siRNA converter software.  The 
oligonucleotides are synthesized, annealed, and ligated into the linearized pSilencer 
vector.  The sip70S6K1 and siSCR plasmids were transfected into OVCAR-3 cells by 
Lipofectamine.  After two weeks selection in medium containing 500 µg/ml G418, the 
clones stably expressing the siRNA were picked and grown in fresh culture dishes.  The 
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cells (5× 105 cells/ml) were cultured in normal medium and lysed, and 50µg of protein 
was analyzed by immunoblotting with the antibodies against total p70S6K1, 
phospho-p70S6K1 (Thr421/Ser424) and β-actin.  (C) The cells expressing p70S6K1 
siRNA or siSCR were cultured and switched to serum-free medium for 16 h before 
treatment with 10% FBS for 1 h at 37°C. Aliquots (50µg) of total proteins were analyzed 
by immunoblotting using antibodies against total p70S6K1 and phopho-S6 ribosomal 
protein (Ser 235/236).   
 
Fig. 8.  Sip70S6K1 inhibited OVCAR-3 cell migration and invasion.  (A) The 
migration assay was conducted by transwell assay.  The cells were split at a ratio of 1:2 
the day before the assay.  The cells were incubated in the transwells at 37°C in 5% CO2 
for 24 h.  Migrated cells were fixed and stained with hematoxylin.  The representative 
fields were photographed.  (B) The migrated cells were counted in three different fields 
per assay under the microscope.  The mean values and the standard error were obtained 
from three independent experiments (P<0.05, Student’s test). (C) OVCAR-3 cells 
expressing sip70S6K1 or siSCR were cultured to near confluence in RPMI 1640 medium 
containing 10% FBS.  The invasion assay was done according to the method mentioned 
above.  The representative fields were photographed.  (D) The cells were enumerated 
by taking photomicrographs at 200x magnification.  The cells in three different fields in 
each experiment were counted.  The mean values and the standard error were from three 
independent experiments (P<0.05, Student’s test). 
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Fig. 9.  Sip70S6K1 decreased cell proliferation and cell cycle-associated protein 
expression.  (A) Cell proliferation was measured by counting OVCAR-3 cells 
expressing sip70S6K1 or siSCR.  OVCAR-3 cells expressing sip70S6K1 or siSCR were 
seeded in a 12-well plate at a density of 2×105 cells/ml in RPMI 1640 medium with 10% 
FBS for 24 h, 48 h, and 72 h.  Cells were harvested and counted using a hemocytometer.  
The number of total cells was counted and normalized to the number obtained in the 
siSCR control at 0 h.  The data represented the mean and the standard error from three 
independent experiments.  * indicates that the cell number was significantly decreased 
when compared to the control at the same time point (P<0.05, Student’s test).  (B) Cells 
expressing sip70S6K1 or siSCR were cultured in a 60 mm dish at a density of 5×105 
cells/dish in RPMI 1640 medium with 10% FBS for 24 h.  The total cellular protein 
extracts were prepared and subjected to immunoblot analysis using specific antibodies 
against phospho-RB (Ser795, Ser780, and Ser807/811), cyclin D1, CDK4, CDK2, cyclin 
E, CDC25A, p27KIP1, p21, PCNA, and β-actin.  The experiments were performed in 
triplicate.  The bands were quantified by scanning densitometry using Eagleeye software. 
The relative mean densitometry between siRNA and siSCR was calculated.  The mean 
ratio±SD was plotted on the graph. 
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Fig. 1. SiP2 inhibited OVCAR-3 cell migration and wound-healing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
p110α
GAPDH
siSCR   siP2 siSCR  siP2
p110α
β-actin
0
0.2
0.4
0.6
0.8
1
1.2
siSCR siP2R
e
la
tiv
e 
ra
te
 
o
f h
ea
lin
gC
*
Re
la
tiv
e 
ra
te
 
o
f h
ea
lin
g
siSCR
siP2
0 h 24 hB
 75
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D
siSCR siP2
E
0
50
100
150
200
250
300
siSCR siP2 
ce
ll 
n
u
m
be
r 
pe
r 
fie
ld
*
ce
ll 
n
u
m
be
r 
pe
r 
fie
ld
 76
Fig. 2. SiP2 decreased OVCAR-3 cell invasion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
siSCR siP2
A
B
0
50
100
150
200
250
siSCR siP2
ce
ll 
n
u
m
be
r 
pe
r 
fie
ld
*
ce
ll 
n
u
m
be
r 
pe
r 
fie
ld
 77
Fig. 3. SiP2 decreased OVCAR-3 cell proliferation. 
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Fig. 4. SiRNA against AKT1 inhibited OVCAR-3 cell migration and wound healing. 
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Fig. 5. SiA1 decreased OVCAR-3 cell invasion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
siSCR siA1
B
0
50
100
150
200
250
siSCR siA1
c
e
ll 
n
u
m
be
r 
pe
r 
fie
ld
*
c
e
ll 
n
u
m
be
r 
pe
r 
fie
ld
 81
Fig. 6. SiA1 decreased OVCAR-3 cell proliferation. 
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Fig. 7. SiP2 and siA1 decreased p70S6K1 activation, and siRNA against p70S6K1 
(sip70S6K1) expression decreased the expression of p70S6K1 protein in OVCAR-3 cells. 
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Fig. 8.  Sip70S6K1 inhibited OVCAR-3 cell migration and invasion. 
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Fig. 9.  Sip70S6K1 decreased cell proliferation and cell cycle-associated protein 
expression. 
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CHAPTER III 
 
TSC2/p70S6K1 regulates tumor growth and angiogenesis through VEGF and 
HIF-1α expression 
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ABSTRACT 
 
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder.  
To study the function of TSC in ovarian tumor angiogenesis, we established stable cell 
lines that expressed small interfering RNA (siRNA) specific to TSC1 or TSC2.  Here, 
we show that inhibition of TSC1 and TSC2 induced the expression of HIF-1α in ovarian 
cancer cells.  Knock-down expression of TSC1 or TSC2 increased VEGF expression at 
both mRNA levels and protein levels.  Lost function of TSC2 induced ovarian tumor 
angiogenesis and tumor growth through p70S6K1 activation.  The 70kDa ribosomal S6 
kinase 1 (p70S6K1) is regulated by TSC2/mTOR pathway.   P70S6K1 is an important 
regulator of both cell proliferation and cell growth.  However, the mechanism of 
p70S6K1 in tumorigenesis remains to be elucidated.  In this study, we specifically 
inhibited p70S6K1 activity in ovarian cancer cells using vector-based siRNA against 
p70S6K1.  We found that the expression of p70S6K1 siRNA significantly decreased 
VEGF protein expression and VEGF transcriptional activation through HIF-1α binding 
site at VEGF promoter.  The expression of p70S6K1 siRNA specifically inhibited 
HIF-1α, but not HIF-1β protein expression in ovarian cancer cells.  We also found that 
p70S6K1 down-regulation decreased ovarian tumor growth and angiogenesis, and that 
p70S6K1 siRNA expression inhibited VEGF expression through decreasing HIF-1α 
expression.  Our data suggested that p70S6K1 might induce tumor angiogenesis by 
increasing HIF-1α and VEGF expression.  This study provides a novel mechanism of 
 87
human ovarian cancer induced by mutations of TSC and the activation of p70S6K1. 
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INTRODUCTION 
 
Tuberous sclerosis complex (TSC) is an autosomal dominant syndrome associated 
with the development of benign and occasional malignant tumors that occurs most 
notably in the central nervous system, kidney, heart, lung and skin 1.  Two genes are 
implicated in tuberous sclerosis: TSC1 2 and TSC2 3.  TSC1 and TSC2 encode the 
protein hamartin and tuberin and are putative tumor suppressor genes 4.  Tuberous 
sclerosis results from mutations in either TSC1 or TSC2 gene.  TSC2 forms a complex 
with TSC1 that inhibits mammalian target of rapamycin (mTOR) 5.  TSC2 has the 
function of GTPase activating protein towards the small Ras-like GTPase Rheb 6.  Rheb 
activates mTOR in its active GTP bound form 7.   
TSC complex is regulated by AMPK 8 and also by the tumor suppressor PTEN9.  
In the absence of PTEN, growth factors stimulate the production of PIP3 leading to the 
activation of AKT and PDK1.  AKT phosphorylates TSC2, which leads to decreased 
TSC2 GAP activity 10-12.  Phosphorylated TSC2 increases the activation of Rheb13 and 
activates mTOR14-16.  Activated mTOR phosphorylates 4E-BP and S6 kinase, leading to 
an increase in the rates of protein translation 17.  
Several studies have implicated the role of VEGF in the TSC pathway in which 
the loss of TSC2 is accompanied by elevated levels of HIF-1α and VEGF 18.  TSC2 loss 
results in the accumulation of HIF-1α and increased expression of HIF-responsive genes 
including VEGF 19.  The regulation of HIF-1 by TSC2 involves mTOR.  HIF-1 levels 
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in TSC2-deficient cells are normalized by treatment with the mTOR inhibitor rapamycin 
20
.  However, the role of TSC/mTOR/p70S6K1 pathway in regulating tumor 
angiogenesis still remains to be elucidated.   In this study, the expression of tuberin and 
harmartin was inhibited by its specific siRNA against TSC1 or TSC2.  The effect of 
downregulation of tuberin or harmartin on HIF-1α and VEGF expression was determined.  
The role of TSC/mTOR/p70S6K1 pathway in ovarian tumor angiogenesis was studied.   
P70S6K1 is activated through PI3K pathway21  and MAPK pathway22.  Recent 
biochemical analyses determined that tuberin also regulates PI3K-dependent activation of 
p70S6K1.  P70S6K1 is known to regulate cell growth by inducing protein synthesis 
components.  Activated PI3K or AKT can induce cell transformation through the 
phosphorylation and activation of p70S6K123.  P70S6K1 is involved in tumor 
progression.  P70S6K1 is overactivated in the majority of human papillary cancer cells24, 
small cell lung cancer cells25 and pancreatic cancer cells26.  Recent studies indicated the 
important role of p70S6K1 in phosphatase and tensin homologue (PTEN) negative and in 
AKT-overexpressing tumors27,28.  It suggests that phosphorylation of p70S6K1 is 
correlated with PI3K induced tumorigenesis.  P70S6K1 is well known to play an 
important role in cell proliferation, cell growth and cell cycle progression, but little is 
known about its role in angiogenesis.  
Angiogenesis is the growth of new vascular endothelial cells and the development 
of new blood vessels.  Tumor expansion cannot proceed beyond 1-2mm without 
angiognesis29.  Angiogenesis is a crucial factor in the progression of solid tumors and 
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metastasis30-32.  VEGF is expressed by many human solid tumors and has been 
implicated in tumor-associated angiogenesis33-37.  VEGF has been found in ovarian 
tumor tissue, omental metastases, cystic and ascitic fluids, and the serum of patients with 
epithelial ovarian cancer38-42.  VEGF overexpression accelerated tumor growth and 
ascites formation, significantly enhanced tumor angiogenesis, and promoted the survival 
of tumor cells in mouse ovarian cancer model43.  VEGF expression is regulated at the 
transcriptional level by hypoxia-inducible factor 1 (HIF-1) under hypoxia and in response 
to growth factor stimulation.  
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein that consists of 
HIF-1α and HIF-1β subunits44.  HIF-1α is degraded during normoxia and HIF-1β is 
constitutively expressed.  In normoxia, HIF-1α is rapidly ubiquitinated by the von 
Hippel-Lindau tumor suppressor E3 ligase complex and subjected to proteasomal 
degradation45,46.  Under hypoxic conditions, HIF-1α is not degraded and accumulates to 
form an active complex with HIF-1β.  Under normal conditions, HIF-1α protein 
synthesis is regulated by activation of the phosphatidylinositol 3-kinase (PI3K)47 and 
ERK mitogen-activated protein kinase (MAPK) pathways48,49.  Recent studies suggest 
that amplified signaling through phosphoinositide 3-kinase and its downstream target, 
mTOR, increases HIF-1-dependent gene expression in certain cell types50,51.  In 
mammals, mTOR is best known to regulate translation through the ribosomal protein S6 
kinases (S6Ks) and the eukaryotic translation initiation factor 4E-binding proteins52.  
The mTOR inhibitor rapamycin appears to be effective against tumors resulting 
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from aberrantly high PI3K signaling53,54.  Rapamycin has been shown to exert its effects 
on growth factor-induced cell proliferation, at least in part, by blocking the activation of 
the p70S6K155, thus preventing the downstream signaling process, such as the activation 
of the members of the cdk family56.  Rapamycin showed antiangiogenesis activity by 
reducing VEGF protein production by tumor cells57.  Rapamycin inhibits both 
stabilization of HIF-1α and transcriptional activity of HIF-1 in hypoxic cancer cells58.  
Rapamycin interferes with HIF-1 activation in hypoxic cells by increasing the rate of 
HIF-1α degradation59.  Rapamycin can inhibit the mTOR activity, thus inhibiting the 
activity of S6K and 4E-BP1.  The effect of rapamycin on angiogenesis suggested that 
p70S6K1 may play a role in tumor angiogenesis.  However, rapamycin may have 
nonspecific effects on tumor angiogenesis.  Thus, we want to specifically knockdown 
the expression of p70S6K1 to determine whether p70S6K1 regulates VEGF expression 
and transcriptional activation and whether p70S6K1 mediated VEGF expression is 
regulated by HIF-1α expression in ovarian cancer cells.  We further investigated the 
roles of p70S6K1 in tumor-associated angiogenesis in vivo. 
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MATERIALS AND METHODS 
 
Reagents and Cell Culture― The antibodies against total p70S6K1, phospho-p70S6K1 
(Thr421/Ser424), phospho-AKT (Ser473), total AKT, phospho-GSK3β (ser-9), total 
GSK3β, phospho-p42/p44 MAPK, total mTOR and total TSC1 were from Cell Signaling 
Technology (Beverly, MA).  Rapamycin and PD98059 were obtained from Calbiochem 
(La Jolla, CA).  The antibodies against total TSC2, total ERK1, and total ERK2 were 
from Santa Cruz Biotechnology (Santa Cruz, CA).  The mouse ABC staining system 
and the rabbit ABC staining system were from Santa Cruz Biotechnology (Santa Cruz, 
CA).  The growth factor-reduced Matrigel and antibodies against HIF-1α and HIF-1β 
were from BD Biosciences (Franklin Lakes, NJ).  Recombinant human insulin and the 
antibody against β-actin were from Sigma (St. Louis, MO).  The horseradish peroxidase 
(HRP)-conjugated anti-rabbit IgG and anti-mouse IgG were from Perkin Elmer Life 
Sciences (Boston, MA).  Factor VIII (Von Willebrand factor) antibody was from Biocare 
Medical (Concord, CA).  The human ovarian cancer cell lines OVCAR-3 and A2780   
were grown in RPMI 1640 (GIBCO BRL, Grand Island, NY) supplemented with 10% 
heat inactivated fetal bovine serum, 2 mM L-glutamine, 0.2% insulin, 100 U/ml penicillin, 
and 100 µg/ml streptomycin, and cultured at 37°C in humidified 5% CO2 incubator.   
 
siRNA and Plasmid Constructs― The siRNA constructs specific to TSC1, TSC2 or 
p70S6K1 were designed using siRNA converter software.  The sequence of double 
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strand small interfering RNA targeted to TSC1, TSC2 and p70S6K1 was as follows: 
TSC1, sense strand, CUGAACCACCACAAGCUACtt, and antisense strand, 
GUAGCUUGUGGUGGUUCAGtt; TSC2ab, sense strand, 
GAAAUUUGAAGAGCACGCAUU, and antisense strand, 
UGCGUGCUCUUCAAAUUUCUU; TSC2cd, sense strand, 
UGAGUCACAGUCCUUUGAGUU, and antisense strand, 
CUCAAAGGACUGUGACUCAUU; TSC2gh, sense strand, 
GGAUUACCCUUCCAACGAAUU, and antisense strand, 
UUCGUUGGAAGGGUAAUCCUU; p70S6K1, sense strand, 
GUUCAAGCUCAUCCAUUCUuu, and antisense strand,  
AGAAUGGAUGAGCUUGAACuu.  A control siRNA that has scramble sequence 
without significant sequence homology to the known gene was also designed.  The 
oligonucleotides were annealed, and ligated into the linearized pSilencer 2.1-U6 vector 
(Ambion, Austin, TX).  The plasmid that expresses siRNA to TSC1, TSC2, p70S6K1 
were named as siTSC1, siTSC2 or sip70S6K1.  The scramble siRNA was named as 
siSCR.  VEGF promoter reporter pGL-Stu1 containing a 2.65 Kb KpnI-BssHII fragment 
of the human VEGF gene promoter was cloned into the pGL2 basic luciferase vector.  
VEGF promoter reporter pMAP11wt, which contains the HIF-1 binding site of VEGF 
5'-flanking sequence (from –985 to –939), was cloned into the pGL2 basic luciferase 
vector as described previously 60.  The mutant VEGF promoter reporter pMAP11mut 
was constructed by introducing a 3-bp substitution into pMAP11wt that abolishes the 
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HIF-1 binding site.  Human HIF-1α gene was inserted into pCEP4 vector as described 
before 61. 
 
Generation of siRNA-expressing cell lines― Cells were plated into 6 well plates.  
SiRNA (2µg) to TSC1 or siSCR was transfected into cells using Lipofectamine 
(Invitrogen), and cultured for 24h without antibiotic selection.  The cells were selected 
with 500 µg/ml G418 (Sigma) for two weeks.  After clonies were formed, the clonies 
were removed and transfered to a fresh 96 well culture plate.  When the cells reached 
confluency in a well of a 96 well culture dish, cells were moved to a well in a 24 well 
culture dish.  When the cells reached confluency, they were split, and cultured with  
250 µg/ml G418 for selection.  Three different clonies were selected and grown.  The 
clonies were named as siTSC1-1, siTSC1-2 and siTSC1-3.  SiRNA(2 µg) to TSC2, 
p70S6K1 or siSCR was transfected into cells using Lipofectamine (Invitrogen) according 
to the manufacturer’s instructions, and cultured for 24h without antibiotic selection.  
Then the cells were cultured in medium containing 500 µg/ml G418 until all of the cells 
in the non-transfected control culture were killed.  The antibiotic-resistant cells were 
pooled together and passaged as needed in medium containing 250µg/ml G418.  
 
Transient transfection and luciferase(luc) assay― Cells were seeded in 12-well plates 
and cultured to 50-60% confluence.  Cells were transiently transfected with siRNA 
plasmid, VEGF reporter and pCMV-β-galactosidase plasmid using Lipofectamine from 
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Invitrogen following the manufacturer’s instructions.  The transfected cells were 
cultured for 16 h, washed once with phosphate-buffered saline (PBS), and lysed with 100 
µl 1×Reporter Lysis Buffer from Promega (Madison, WI, USA).  Luciferase substrate 
was added to protein samples (10 µl) for the luciferase assay and measured by a 
monolight luminometer.  β-Galactosidase (β-gal) activity was measured by incubation in 
assay buffer (100 mM phosphate, pH 7.5, 2 mM MgCl2, 100 mM β-mercaptoethanol, 1.33 
mg/mL o-nitrophenyl β-D-galactopyranoside) at 37 °C for 1 h.  Relative Luc activity 
was calculated as the ratio of Luc/β-gal activity and normalized to that from the control 
cells.  
 
Immunoblotting Analysis― Cells were harvested and lysed in RIPA buffer [150 mM 
NaCl, 100 mM Tris (pH 8.0), 1% Triton X-100, 1% deoxycholic acid, 0.1% SDS, 5 mM 
EDTA, and 10 mM NaF], supplemented with protease inhibitors.  Protein 
concentrations were determined by the Bradford assay (Bio-Rad).  The total cellular 
protein extracts were separated by SDS-PAGE and transferred to nitrocellulose membrane.  
Membranes were blocked with 5% nonfat dry milk in PBS containing 0.05% Tween 20, 
and incubated with the primary antibodies against total p70S6K1, phospho-p70S6K1 
(Thr421/Ser424), phospho-AKT (Ser473), total AKT, phospho-GSK3β (ser-9), total 
GSK3β, phospho-p42/p44 MAPK, HIF-1α and HIF-1β, total mTOR, total TSC1, total 
TSC2, total ERK1, total ERK2 and β-actin.  Bound antibodies were detected with an 
appropriate HRP-conjugated secondary antibody (Pierce) and chemiluminescence 
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(Pierce).  To use the same membrane to detect several proteins, the blots were incubated 
with gentle shaking in stripping buffer (50mM glycine, 100mM KCl, 0.5mM EDTA, 
2-mercoptomethanol, 7M guandine hydrochloride) for 15 min at room temperature and 
washed three times with wash buffer for 15 min each time before reblotting the 
membranes using certain antibodies designed for the next experiment. 
 
Quantification of VEGF protein― The levels of VEGF protein in the medium were 
determined by a VEGF ELISA kit (R&D Systems).  The cells were seeded in 12-well 
plates and cultured to 90–100% confluence.  Cells were changed to fresh complete 
medium.  The supernatants were collected and the cell numbers in each well were 
counted after 16 h incubation.  VEGF in the supernatant (100 µL) was determined and 
normalized to the cell numbers.  A standard curve was obtained by a serial dilution of 
human recombinant VEGF.  The data were presented as mean ± SD from three different 
experiments. 
 
Semi-Quantitative RT-PCR― Total RNAs were isolated from 1 x 106 cultured cells with 
Trizol reagent (Invitrogen) according to the instruction of the manufacturer.  First-strand 
cDNAs were synthesized from 1 µg of total RNAs using AMV Reverse Transcriptase, an 
oligo(dT) primer and dNTP (Promega).   Primers used for amplification were as follows: 
VEGF forward, 5’-TCGGGCCTCCGAAACCAT-3’; VEGF reverse, 
5’-CCTGGTGAGAGATCTGGT-3’; GAPDH forward, 
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5’-CCACCCATGGCAAATTCCATGGCA-3’; GAPDH reverse 
5’-TCTAGACGGCAGGTCAGGTCCACC-3’.  Each RT-PCR reaction consisted of 30 
cycles of 1 min at 94°C, 1 min at 60°C and 1 min at 72°C.  PCR products were run on 
2% agarose gels, stained with ethidium bromide, and photographed using Eagleeye 
system. 
 
Chicken Chorioallantoic Membrane (CAM) angiogenesis assay— White Leghorn 
chicken eggs were fertilized and incubated at 37°C with 70% humidity.  An artificial air 
sac was created over a region containing small blood vessels in the chicken 
chorioallantoic membrane (CAM) as described previously62.  Human ovarian cancer 
OVCAR-3 cells that expressed siRNA to TSC2, p70S6K1 or siSCR were trypsinized, 
washed, and resuspended at 10 x 107 cells/ml in serum-free RPMI 1640 medium and 
mixed with 10% Matrigel (Collaborative Biomedical Products, Bedford, MA).  Aliquots 
(20 µl) of the mixture (two million cells) or the Matrigel alone were placed on the CAM 
of 9 days old chicken embryos.  Five days after implantation, tumors in CAM were 
photographed using a Nikon digital camera.  The experiments were repeated two times 
with five embryos for each treatment, and representative fields were photographed.  The 
relative blood vessel density was determined by measuring the number of blood vessel 
branch points in a unit area on the CAM.  Data were expressed as the mean± SD from 
replicate experiments.  
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Immunohistochemistry—Tissues harvested from the CAMs were fixed in 10% 
formaldehyde, then embedded in paraffin (OCT; Miles Inc., IndianaB.C.).  Tissue 
sections were deparaffinized in 3x xylene for 5 min each, in 2x 100% alcohol for 10 min 
each, in 2x 95% alcohol for 10 min each, and then rinsed three times in deionized water.  
The slides were then boiled with antigen retrieval buffer (10 mM sodium citrate, pH 6.0) 
for 1 min at full power followed by 9 min at medium power using microwave, cooled for 
20 min, then rinsed in deionized water three times for 5 min each.  The slides were 
incubated in 1% hydrogen peroxide for 10 min and washed in deionized water three times 
for 5 min each.  The slides were incubated with 5% goat serum at room temperature for 
1 h, and then stained with antibodies against Factor VIII (1:100), VEGF (1:100) and 
HIF-1α (1:100).  The sections were incubated in a humid chamber at 4ºC overnight.  
After three washes in 1x PBS, the slides were incubated for 30 min with biotinylated 
secondary antibody, and detected by the incubation with AB enzyme reagent for 30 min 
at room temperature.  Sections were rinsed several times in 1x PBS.  One to three 
drops of peroxidase substrate were added to the slides for 5-10 min, and washed once 
with water.  The slides were counterstained with hemotoxylin and washed several times 
with water.  The sections were dehydrated as follows: 2x 95% ethanol for 10 seconds 
each, 2x 100% ethanol for 10 seconds each, 3x xylenes for 10 seconds each.  After 
xylene goes off, the slides were immediately added with 1-2 drops of permanent 
mounting medium and covered with a glass coverslip.  The slides were observed under 
light microscope and photographed. 
 99
Statistical Analysis—The data were analyzed using SPSS statistics software package 
(SPSS, Chicago, IL).  All of the results are expressed as mean ± SD from three 
independent experiments except where that are specifically indicated, and the difference 
at P < 0.05 was considered significant.  
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RESULTS 
 
Expression of TSC1 or TSC2 siRNA induced HIF-1α expression―TSC2 loss results in 
the accumulation of HIF-1α and increased expression of HIF-responsive genes including 
VEGF in mouse embryo fibroblast cells.  However the mechanism of regulation of 
HIF-1 expression by TSC1 and TSC2 is unknown.  To determine whether TSC1 and 
TSC2 regulate HIF-1 expression in ovarian cancer cells, we established the stable cell 
lines OVCAR-3 that expressed siRNA against siSCR, TSC1 or TSC2.  To determine the 
effect of siTSC1 expression on HIF-1α protein level, the ovarian cancer cells that stably 
expressed siTSC1 or siSCR were cultured in complete medium for 24 h or in serum-free 
medium for 24 h and treated with insulin for 6 h.  Whole cell lysates were analyzed by 
immunoblotting using antibodies against HIF-1α and HIF-1β proteins.  SiTSC1 
expression increased HIF-1α protein level in complete medium compared to that in 
control cells (Fig. 1A).  HIF-1α protein level was induced in cells expressing siTSC2 in 
complete medium compared to that in control cells (Fig. 1B).  SiTSC1 expression 
induced a higher level of HIF-1α protein expression in serum-free medium than that in 
control cells (Fig. 1C).  In contrast to siSCR cells, TSC2-knock down cells failed to 
downregulate HIF-1α in response to growth factor deprivation (Fig. 1D).    
 
Expression of siTSC1 or siTSC2 increased VEGF protein expression and mRNA 
level―VEGF plays an important role in human tumorigenesis and angiogenesis.  
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However, the mechanism of its elevation in human cancer cells with TSC mutations still 
remains to be elucidated.  To determine the role of TSC1 and TSC2 in regulating VEGF 
protein level, we established the stable cell lines OVCAR-3 that expressed siTSC1, 
siTSC2 or siSCR.  The VEGF protein levels in the medium of cells expressing siTSC1, 
siTSC2 or siSCR were determined by ELISA.  To exclude the effect of cell proliferation 
on the expression of VEGF protein, we normalized the VEGF protein concentration to 
the total cell number.  As shown in Fig. 2A, siTSC1 or siTSC2 expression increased 
VEGF protein levels in OVCAR-3.  To determine if siTSC1 or siTSC2 expression could 
regulate VEGF expression at the mRNA level, we performed semiquantitative RT-PCR.  
Expression of siTSC1 or siTSC2 induced the mRNA expression of VEGF compared to 
that in control cells (Fig. 2B).  
 
Expression of TSC1 or TSC2 siRNA in the cells induced p70S6K1 and ERK1/2 activation, 
and decreased the phosphorylation of AKT and GSK3β―To determine the signal 
pathway that TSC1 regulates HIF-1 expression in ovarian cancer cells, we established the 
stable cell lines OVCAR-3 that express siRNA to TSC1.  Total TSC1 protein was 
reduced in cells expressing siTSC1 (Fig. 3A).  The activity of p70S6K1 and ERK1/2 
was induced in cells expressing siTSC1 compared to siSCR control in complete medium 
(Fig. 3B).  Serum deprivation failed to block S6 phosphorylation and ERK1/2 
phosphorylation in cells expressing siTSC1 (Fig. 3C).   The AKT phosphorylation at 
Ser-473 and GSK3β phosporylation at Ser-9 were inhibited in cells expressing siTSC1 
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compared to that in siSCR control in both complete medium (Fig. 3B) and serum-free 
medium in the presence or absence of insulin (Fig. 3C).   
Loss of expression of tuberin plays a role in angiogenesis.  To determine the 
signal pathway that TSC2 regulates HIF-1 expression in ovarian cancer cells, we 
established the stable cell lines OVCAR-3 that express siRNA to TSC2.  Three different 
siRNA targeted to different region of TSC2 gene were utilized and three stable cell line 
that express siRNA to TSC2 were established.  They were named as siTSC2ab, 
siTSC2cd and siTSC2gh.  In contrast to a scrambled siRNA, total TSC2 protein was 
markedly reduced by expression of siTSC2 (Fig. 4A).  The level of phosphorylated 
p70S6K1 and phosphorylated ERK1/2 was higher in cells expressing siTSC2 than that in 
siSCR control cells under the condition of complete medium (Fig. 4A) or serum-free 
medium treated with or without insulin (Fig. 4B).  The expression of siTSC2 inhibited 
the activity of AKT and GSK3β in both complete medium (Fig. 4A) and serum-free 
medium in the presence or absence of insulin (Fig. 4B).  The results suggested that loss 
of TSC1 or TSC2 might regulate HIF-1 and VEGF expression through p70S6K1 and 
ERK1/2 and not through AKT in ovarian cancer cells. 
 
siTSC2 expression induced ovarian tumor angiogenesis and tumor growth through 
mTOR/p70S6K1―To determine whether tuberin regulated tumor-induced angiogenesis 
through mTOR/p70S6K1 in vivo, cells expressing siTSC2 treated with DMSO or 10 nM 
rapamycin, and cells expressing siTSC2 infected with adenovirus vector or with 
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adenovirus expressing p70S6K1(K100R) were mixed with Matrigel, and implanted onto 
the CAM of 9-day-old embryos.  The cells expressing siSCR were used as the control. 
The relative blood vessel numbers were increased in tumors generated from the cells that 
expressed siTSC2 when compared to the siSCR control group (Fig. 5).  This result 
showed that loss of TSC2 induced tumor angiogenesis.  The number of blood vessels 
was decreased in siTSC2 treated with 10 nM rapamycin in contrast to that in siTSC2 
treated with DMSO.  The group of siTSC2 infected with adenovirus expressing 
p70S6K1 (K100R) has less blood vessel formation when compared to the cells 
expressing siTSC2 infected with adenovirus vector (Fig. 5).  
To test the effect of siTSC2 expression on tumor growth, OVCAR-3 cells stably 
expressing siTSC2 or siSCR were mixed with Matrigel, and implanted onto the CAMs as 
described above.  The cells were incubated in the CAMs for 9 days at 37°C.  Tumor 
weight generated from the cells with siTSC2 expression was two times that in the control 
suggesting the loss of TSC2 induced tumor growth (Fig. 6B).  Tumors from cells 
expressing siTSC2 pretreated with rapamycin have a significantly decreased tumor 
weight compared to that of cells expressing siTSC2.  Tumor weight from cells 
expressing siTSC2 infected with adenovirus expressing p70S6K1 (K100R) was 50% of 
that in the cells expressing siTSC2 infected with adenovirus vector (Fig. 6B).  This 
result demonstrated that TSC2 induced tumor growth through p70S6K1 activation.  
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P70S6K1 was a downstream molecule that mediated the effect of TSC1 or TSC2 on 
VEGF transcriptional activation― To determine the mechanism through which TSC2 
regulates VEGF expression, OVCAR-3 cells were transiently transfected with a VEGF 
promoter reporter containing 2.6-kb human VEGF promoter with or without presence of 
siTSC1 or siTSC2 construct.  SiTSC1 expression or siTSC2 expression induced VEGF 
transcriptional activation in a dose-dependent manner (Fig. 7A).  Overexpression of 
sip70S6K1 reduced the VEGF reporter activity induced by expression of siTSC1 or 
siTSC2 to normal (Fig. 7B).  Expression of TSC1 or TSC2 inhibited VEGF 
transcriptional activation in a dose-dependent manner (Fig. 7C).  Overexpression of the 
p70S6K1 active form reversed the VEGF reporter activity inhibited by expression of 
TSC2 or TSC1 (Fig. 7D).  
To determine the role of p70S6K1 in regulating VEGF protein level, we 
established the stable cell lines OVCAR-3 and A2780 cells that expressed siRNA against 
p70S6K1 (sip70S6K1) or siSCR.  The VEGF protein levels in the medium of cells 
expressing sip70S6K1 or siSCR were detected by ELISA assay.  As shown in Fig. 8A 
and 8B, sip70S6K1 expression significantly decreased VEGF protein levels in OVCAR-3 
and A2780 cells.   
To further determine the mechanism through which p70S6K1 regulates VEGF 
expression, A2780 or OVCAR-3 cells were transiently transfected with a VEGF promoter 
reporter containing 2.6-kb human VEGF promoter with or without presence of 
sip70S6K1 construct.  Sip70S6K1 expression inhibited VEGF transcriptional activation 
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in a dose-dependent manner (Fig. 8C).  The results showed that p70S6K1 regulated 
VEGF expression at the transcriptional level.  To test whether the HIF-1 binding site at 
the VEGF promoter is important for p70S6K1- mediated transcriptional activation, we 
analyzed the effect of sip70S6K1 expression on a short form of VEGF promoter reporter, 
pMAP11WT which contained a functional promoter fragment with the HIF-1 binding site. 
The OVCAR-3 and A2780 cells were cotransfected with pMAP11wt reporter and 
sip70S6K1 construct.  The cells cotransfected with pMAP11wt reporter and siSCR were 
used as a control.  Sip70S6K1 expression significantly decreased pMAP11wt reporter 
activity (p < 0.05) (Fig. 8D).  Overexpression of HIF-1α reversed the pMAP11wt 
reporter activity inhibited by expression of sip70S6K1 (Fig. 8D), suggesting that 
sip70S6K1 inhibited VEGF transcriptional activation via HIF-1α DNA binding site and 
HIF-1α protein expression.  To test whether the inhibitory effect of sip70S6K1 on 
VEGF transcriptional activity required the HIF-1 binding site, we employed a mutant 
pMAP11mut VEGF promoter reporter that had 3 bp substitutions at the HIF-1 binding 
site.  The cells were cotransfected with pMAP11mut VEGF promoter reporter and 
sip70S6K1.  We found that sip70S6K1 expression did not inhibit the pMAP11mut 
VEGF reporter activity (Fig. 8E), further confirming that p70S6K1 regulates VEGF 
transcriptional activation through HIF-1α DNA binding site. 
 
Sip70S6K1 expression inhibited HIF-1α expression―To determine the effect of 
sip70S6K1 expression on HIF-1α protein level, the ovarian cancer cells that stably 
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expressed sip70S6K1 or siSCR were cultured in complete medium for 24 h or in 
serum-free medium for 24 h and treated with insulin for 6 h.  Whole cellular lysates 
were analyzed by immunoblotting using antibodies against HIF-1α and HIF-1β proteins.  
Sip70S6K1 expression decreased HIF-1α protein level in complete medium compared to 
that in vector control cells (Fig. 9A).  Insulin induced HIF-1α, but not HIF-1β 
expression in the control cells.  Sip70S6K1 expression abolished insulin-induced 
HIF-1α protein expressions, showing that p70S6K1 may activate VEGF transcription 
specifically through HIF-1α expression in the ovarian cancer cells (Fig. 9B).                            
 
Sip70S6K1 expression inhibited tumor induced angiogenesis and tumor growth in vivo― 
To test whether specific inhibition of p70S6K1 affected tumor-induced angiogenesis in 
vivo, OVCAR-3 cells stably expressing sip70S6K1 or siSCR were mixed with Matrigel, 
and implanted onto the CAM of 9-day-old embryos, and then incubated for 5 days at 
37°C.  OVCAR-3 cells induced angiogenesis, which was inhibited by sip70S6K1 
expression with a 60% reduction of angiogenesis when compared to the Matrigel alone in 
the CAM (Fig. 10B).  To determine whether sip70S6K1 expression inhibited 
angiogenesis in the tumors, tumor sections were stained using antibodies against Factor 
VIII, which reacts specifically with the endothelial cells of blood vessels.  We found that 
sip70S6K1 expression greatly decreased angiogenesis in tumors (p < 0.05) (Fig. 10C).  
To test the effect of sip70S6K1 expression on tumor growth, OVCAR-3 cells stably 
expressing sip70S6K1 or siSCR were mixed with Matrigel, and implanted onto the 
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CAMs as described above.  The cells were incubated in the CAMs for 9 days at 37°C.  
Tumor weight generated from the cells with sip70S6K1 expression was only 25% of that 
in the control (Fig. 10E).  We also determined the expression of sip70S6K1 on affecting 
phospho-p70S6K1 and total p70S6K1 levels in the tumor tissues.  Total proteins were 
extracted from three tumors in each group, and phospho-p70S6K1 and total p70S6K1 
proteins were detected by immunoblotting.  Sip70S6K1 expression significantly 
inhibited phospho-p70S6K1 and total p70S6K1 expression (Fig. 10F).  
 
Sip70S6K1 Expression Decreased VEGF and HIF-1α expression in tumors― To 
determine whether sip70S6K1 expression inhibits VEGF and HIF-1α expression in vivo, 
tumor sections were stained using antibodies against VEGF or HIF-1α.  We found that 
sip70S6K1 expression significantly decreased the signals of VEGF or HIF-1α in tumor 
sections (Fig. 11A).  We also determined the effect of sip70S6K1 expression on HIF-1α 
and HIF-1β protein levels by immunoblotting in tumors.  Sip70S6K1 expression 
significantly decreased the expression of HIF-1α.  HIF-1β protein expression was not 
changed (Fig. 11B).  This result showed that sip70S6K1 specifically regulated HIF-1α, 
but not HIF-1β expression in vivo. 
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DISCUSSION 
           
The tumor-suppressor proteins TSC1 and TSC2 are associated with an autosomal 
dominant disorder known as tuberous sclerosis complex (TSC).  TSC1/TSC2 complex is 
known to play a role in regulating VEGF through mTOR dependent pathway in mouse 
embryo fibroblasts cells.  In this study, we showed that downregulation of TSC1 or 
TSC2 with their siRNA constructs upregulated HIF-1α in ovarian cancer epithelial cells.  
The activation of p70S6K1 and ERK1/2 was induced in cells expressing siTSC1 or 
siTSC2.  It suggests that TSC1/TSC2 complex may regulate the expression of HIF-1α 
through MAPK or p70S6K1.  Activated p70S6K1 may inhibit AKT activation through a 
negative feedback loop from mTOR/S6K to the adaptor molecule IRS-1.  A similar 
negative feedback involving S6K repression of AKT activation has also been described in 
Drosophila 63.  The increase in HIF-1α levels in cells expressing siTSC1 or siTSC2 is 
functionally important as it is accompanied by increased expression of VEGF.  VEGF 
has a very important role in tumor growth and angiogenesis.  To determine the effect of 
siTSC2 in tumor progression, we performed tumor angiogenesis and tumor assay using 
CAM model.  Expression of siRNA to TSC2 in tumor cells induced tumor growth and 
angiogenesis (Fig. 6B and Fig. 10B).  The increased tumor growth and angiogenesis can 
be inhibited by rapamycin and p70S6K1 (K100R) expression.   These data are 
consistent with a model that downregulation of TSC2 results in activation of 
mTOR/p70S6K1, which increases HIF-1α and VEGF and leads to increased tumor 
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growth and angiogenesis. 
P70S6K1 is known to play an important role in cell proliferation and cell cycle 
progression.  Growth factors activate p70S6K1 through the activation of PI3K and 
mTOR.  PI3K activation is necessary and sufficient for the activation of p70S6K1 which 
specifically phosphorylates the ribosomal protein S6 which is required for cells to enter 
the S phase after mitogenic stimulation64.  Rapamycin is implicated in tumor growth.  
Inhibition of mTOR activity with rapamycin resulted in G1 arrest in ovarian cancer cells 
with increased AKT activity65,66.  Rapamycin effectively inhibits tumor growth that 
depend on AKT signaling for proliferation in a genetically defined mouse ovarian 
carcinoma model67.  Rapamycin has demonstrated antiangiogenic effects in in vivo 
mouse model68.  However, there is no direct evidence in the role of p70S6K1 in 
angiogenesis.  In this study we showed that specifically knockdown of p70S6K1 
expression decreased ovarian cancer tumor growth and angiogenesis in vivo (Fig. 10).  
We also showed that p70S6K1 played an important role in the regulation of VEGF and 
HIF-1α expression (Fig. 8).  VEGF is overexpressed in most human tumors including 
ovarian cancer.  VEGF stimulates angiogenesis and tumor growth.  VEGF is becoming 
an important target for cancer treatment.   In this paper we have demonstrated that 
inhibition of p70S6K1 expression decreased VEGF expression at the transcriptional level 
in ovarian cancer cells (Fig. 8).  It suggested that p70S6K1 might regulate ovarian 
cancer angiogenesis through VEGF expression.  VEGF expression is regulated through 
at least three mechanisms including gene transcription, gene translation level, and mRNA 
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stabilization.  To investigate the mechanism of p70S6K1-mediated VEGF expression, 
we used a VEGF promoter-reporter gene construct and demonstrated that p70S6K1 
down-regulation decreased VEGF expression at the transcriptional level.  
The transcriptional regulation of VEGF is mainly mediated by HIF-1.  Recently, 
growth factors were shown to increase expression of HIF-1α and HIF-1α mediated 
VEGF transcriptional activation via a PI3K mechanism69-72.  In this study we 
demonstrated that p70S6K1 regulates VEGF transcriptional activation through HIF-1α, 
but not HIF-1β subunit.  We also showed that p70S6K1 is required for VEGF and 
HIF-1α expression in tumor tissues.  This study provides strong evidence to suggest that 
p70S6K1 may regulate ovarian cancer angiogenesis through VEGF and HIF-1α 
expression. 
In summary, these results suggest that downregulation of TSC2 increased tumor 
growth and angiogenesis through mTOR/p70S6K1 pathway.  We demonstrate here for 
the first time that p70S6K1 down-regulation inhibits expression of VEGF at the 
transcriptional level through HIF-1α expression and inhibition of p70S6K1 expression 
decreased ovarian tumor growth and angiogenesis in vivo.  This novel finding provides a 
mechanism for potentially targeting p70S6K1 for human ovarian cancer therapy in the 
future.  
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FIGURE LEGENDS 
 
Figure 1. SiTSC1 or siTSC2 expression induced HIF-1α expression in both complete 
medium and serum-free medium. (A) OVCAR-3 cells expressing siSCR or siTSC1 
were split at the density of 5×105 cells/dish and cultured in complete medium for 24 h. 
Aliquots (30 µg) of total cellular proteins were analyzed by immunoblotting using 
antibodies against HIF-1α and HIF-1β. (B) OVCAR-3 cells expressing siSCR or siTSC2 
were split at the density of 5×105 cells/dish and cultured in complete medium for 24 h. 
The HIF-1α and HIF-1β protein levels were analyzed by immunoblotting analysis. (C) 
OVCAR-3 cells expressing siSCR or siTSC1 were split at the density of 5×105 cells/dish, 
followed by the treatment with serum-free medium for 24 h.  The cells were incubated 
in the absence or presence of 100 nM insulin for 6 h.  Protein levels of HIF-1α and 
HIF-1β within the cellular lysates were determined by immunoblotting assay using 
HIF-1α and HIF-1β antibody. (D) OVCAR-3 cells expressing siSCR or siTSC2 were 
split at the density of 5×105 cells/dish, followed by the treatment with serum-free medium 
for 24 h.  Cells were switched to the serum-free medium in the presence or absence of 
100 nM insulin for 6 h.  Aliquots (30 µg) of total cellular proteins were analyzed by 
immunoblotting using antibodies specific for HIF-1α and HIF-1β.  
 
Figure 2. SiTSC1 or siTSC2 expression induced VEGF protein expression and 
VEGF mRNA level in ovarian cancer cells. (A) OVCAR-3 cells stably expressing 
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siTSC1, siTSC2 or siSCR were cultured to 100% confluence.  The cells were changed 
to fresh complete medium overnight.  Aliquots of cell supernatants were collected and 
analyzed for VEGF protein levels by ELISA. (B) OVCAR-3 cells stably expressing 
siTSC1, siTSC2 or siSCR were seeded at the density of 5×105 cells/dish.   After cells 
were grown to 70% confluence, cells were collected and total RNAs were extracted using 
Trizol reagent.  The total RNAs were prepared and first strand cDNAs were synthesized 
using AMV Reverse Transcriptase and oligo(dT) primer.  VEGF mRNA in OVCAR-3 
cells expressing siTSC1, siTSC2 or siSCR was assayed by semiquantitative RT-PCR.  
The products of PCR were resolved on 2% agrose gel and photographed using Eagle-eye 
system.  
 
Figure 3. Expression of siTSC1 induced p70S6K1 and ERK1/2 activation, and 
decreased levels of AKT and GSK3β phosphorylation. (A) OVCAR-3 cells stably 
expressing siTSC1 or siSCR were seeded at a density of 5×105 cells/dish.  The total 
cellular protein extracts were prepared and subjected to immunoblotting analysis using 
antibodies against total mTOR, phospho-p70S6K1 (Thr421/Ser424), phospho-AKT 
(Ser473), total AKT and β-actin. (B) OVCAR-3 cells stably expressing siTSC1 or siSCR 
plasmid were cultured in a 60 mm dish at a density of 5×105 cells/dish overnight, 
followed by the incubation with serum-free medium for 24 h.  Cells were stimulated 
with or without 100 nM insulin for 1 h as indicated.  Cellular extracts were subjected to 
immunoblotting analysis with phospho-specific antibodies to compare levels of p70S6K1 
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phosphorylation at Thr-421 and Ser-424, AKT phosphorylation at Ser-473, GSK3β 
phosporylation at Ser-9, and ERK1/2 phosphorylation at Thr-202 and Tyr-204.  Levels 
of total AKT, total p70S6K1, total ERK1/2 and β-actin were used as a control. 
 
Figure 4. Expression of siTSC2 induced p70S6K1 and ERK1/2 activation, and 
decreased levels of AKT and GSK3β phosphorylation. (A) OVCAR-3 cells stably 
expressing siTSC2 or siSCR were seeded at a density of 5×105 cells/dish, cultured for 24 
h at 37 °C in 5% CO2.  Aliquots (30 µg) of total cellular proteins were analyzed by 
immunoblotting using antibodies specific to total TSC2, phospho-p70S6K1 
(Thr421/Ser424), total p70S6K1, phospho-AKT (Ser473), total AKT, p-GSK3β (Ser9), 
total GSK3β, phospho p42/p44 MAPK, total ERK1/2 and β-actin. (B) OVCAR-3 cells 
stably expressing siTSC2 or siSCR were cultured in a 60 mm dish at a density of 5×105 
cells/dish overnight, followed by the treatment with serum-free medium for 24 h.  Cells 
were switched to the serum-free medium in the presence or absence of 100 nM insulin for 
1 h.  Protein (30 µg) of total cellular lysate was used for detection of p70S6K1 
phospho-Thr-421/Se-r424, AKT phospho-Ser-473, GSK3β phospho-Ser-9, and ERK1/2 
phospho-Thr-202 /Tyr-204.  Levels of total AKT, total p70S6K1, total ERK1/2 and 
β-actin were used as a control. 
 
Figure 5. SiTSC2 expression induced ovarian tumor angiogenesis through 
mTOR/p70S6K1 pathway. (A) OVCAR-3 cells stably expressing siTSC2 were treated 
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with 10 nM rapamycin or the solvent for 12 h.  OVCAR-3 cells stably expressing 
siTSC2 were infected with 15 MOI adenovirus vector or adenovirus expressing p70S6K1 
(K100R) for 24 h.  Cells were collected in serum-free medium at the concentration of 10 
x 107 cells/ml in serum-free RPMI 1640, which contained 5% Matrigel without growth 
factor.  Aliquots (20 µl) of the mixture (two million cells) were implanted onto the 
CAM of 9-day-old chicken embryos.  Tumors in the CAM were photographed 5 days 
after implantation.  The experiments were repeated two times with five embryos for 
each group, and representative fields were photographed. (B) The relative blood vessel 
density was determined by measuring the number of blood vessel branch points in a unit 
area on Day 5.  Data are expressed as mean ±SD from replicate experiments, and 
normalized to results obtained with the CAMs implanted by the cells expressing siSCR.  
* indicates a significant difference from the siSCR control group (p < 0.05).   # 
indicates a significant difference in tumor weight from the siTSC2 group (p < 0.05).  (C) 
Tumor sections were stained by Factor VIII (Von Willebrand factor) antibody.  The 
signals were detected using the rabbit ABC staining system.  The pictures were taken 
under Olympus microscope at the magnification of 160×.  Negative control was set that 
the section was incubated in the presence of the primary antibody without the secondary 
antibody. 
 
Figure 6. SiTSC2 expression induced tumor growth in vivo. (A) OVCAR-3 cells 
stably expressing siTSC2 were treated with DMSO or with 10 nM rapamycin for 12 h.  
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OVCAR-3 cells stably expressing siTSC2 were infected with 15 MOI adenovirus vector 
or adenovirus expressing p70S6K1 (K100R) for 24 h.  Cells were collected in 
serum-free medium and mixed with the equal volume of Matrigel without growth factor.  
The mixture was placed on the CAM of 9-day-old chicken embryos.  The tumors were 
harvested after 9-day incubation.  The tumors were weighed and fixed in 10% formalin.  
Representative tumor pictures from different treatments were taken. (B) Tumor weight 
was obtained from four different embryos for each treatment with two replicate 
experiments.  The mean±SD were obtained from eight replicate tumors.  * indicates a 
significant difference from the siSCR control group (p < 0.05).  # indicates a significant 
difference when compared to the siTSC2 group (p < 0.05). 
 
Figure 7. P70S6K1 was a downstream molecule that mediated siTSC2-induced 
VEGF transcriptional activation. (A) Cells were seeded in 12 well plates and cultured 
to 40-50% confluence.  Cells were transiently transfected with VEGF promoter reporter 
pGL-Stu1, pCMV-β-galactosidase plasmid, siTSC1 and siTSC2 at the concentrations as 
indicated.  The empty vector was added to make total transfected DNA to 1.15 µg.  
The relative luciferase activity was determined as described above. * indicates a 
significant difference when compared to the control (p < 0.05). (B) Cells were transiently 
transfected with VEGF promoter reporter pGL-Stu1, pCMV-β-galactosidase plasmid, 
siTSC1, siTSC2 and sip70S6K1 plasmid at the concentrations as indicated.  The empty 
vector was added to make total transfected DNA to 1.25 µg.  The relative luciferase 
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activity was determined as described above. * indicates a significant difference when 
compared to the siTSC1 group (p < 0.05).  # indicates a significant difference when 
compared to the siTSC2 group (p < 0.05). (C) Cells were transiently transfected with 
VEGF promoter reporter pGL-Stu1, pCMV-β-galactosidase plasmid, TSC1 and TSC2 
plasmid at the concentrations as indicated. The empty vector pRK7 was added to make 
total transfected DNA to 1.15µg.  The relative luciferase activity was determined. * 
indicates a significant difference when compared to the control (p < 0.05).  (D) Cells 
were transiently transfected with VEGF promoter reporter pGL-Stu1, 
pCMV-β-galactosidase plasmid, TSC1, TSC2 and p70S6K1 active form plasmid at the 
concentrations as indicated. The empty vector was added to make total transfected DNA 
to 1.25 µg.  The relative luciferase activity was determined.  Statistical analysis was 
performed by ANOVA software at a significance level of P <0.05.  Data are mean ± SD 
from 3 independent experiments.  Each experiment was performed with triplicate 
cultures.  * indicates a significant difference when compared to the control (p < 0.05).  
# indicates a significant difference when compared to the TSC1 group (p < 0.05).  ∆ 
indicates a significant difference when compared to the TSC2 group (p < 0.05). 
 
Figure 8. Sip70S6K1 expression inhibited VEGF protein expression and VEGF 
transcriptional activation via HIF-1α DNA binding site. (A) OVCAR-3 cells stably 
expressing sip70S6K1 or siSCR were cultured to 100% confluence.  The cells were 
changed to fresh complete medium.  Aliquots of cell supernatants were collected and 
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analyzed for VEGF protein levels by ELISA. (B) A2780 cells stably expressing 
sip70S6K1 or siSCR were cultured to 100% confluence.  The cells were changed to 
fresh complete medium.  Aliquots of cell supernatant were collected and analyzed for 
VEGF protein levels by ELISA.  Data are mean ± SD from 3 independent experiments.  
Statistical analysis was performed by Student’s t test at a significance level of P <0.05. 
*Significantly decreased VEGF when compared to that of control, P <0.05. (C) Cells 
were seeded in 12 well plates and cultured to 40-50% confluence.  Cells were 
transiently transfected with VEGF promoter reporter pGL-Stu1, pCMV-β-galactosidase 
plasmid, sip70S6K1 and wild-type HIF-1α plasmid at the concentrations as indicated.  
The empty vector was added to make total transfected DNA to 1.15 µg. (D) Cells were 
transfected with pMAP11wt reporter, β-gal plasmid, sip70S6K1 and wild-type HIF-1α 
plasmid at the concentrations as indicated. (E) Cells were transfected with pMAP11 
mutant reporter, β-gal plasmid and sip70S6K1 at the concentrations as indicated.  
Statistical analysis was performed by ANOVA software at a significance level of P <0.05.  
* indicates a significant difference when compared to the control (p < 0.05). 
 
Figure 9. Sip70S6K1 expression inhibited HIF-1α protein expression in ovarian 
cancer cells. (A) OVCAR-3 cells or A2780 cells stably expressing sip70S6K1 or siSCR 
were seeded in 60 mm plates in RPMI 1640 medium with 10% FBS for 24 h.  The total 
cellular protein extracts were prepared, and subjected to immunoblotting analysis using 
specific antibodies against HIF-1α and HIF-1β. (B) OVCAR-3 cells or A2780 cells 
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stably expressing sip70S6K1 or siSCR plasmid were cultured in a 60 mm dish at a 
density of 5×105 cells/dish in RPMI 1640 medium with 10% FBS for 24 h at 37°C in 5% 
CO2 incubator, followed by the incubation with serum-free medium for 24 h.  Cells 
were switched to the medium in the presence or absence of 100 nM insulin for 6 h as 
indicated.  The total cellular protein extracts were prepared and subjected to 
immunoblotting analysis using antibodies against HIF-1α and HIF-1β. 
 
Figure 10. Sip70S6K1 expression inhibited ovarian tumor angiogenesis and tumor 
growth. (A) Two million OVCAR-3 cells expressing siSCR or sip70S6K1 were collected 
in serum-free medium and mixed with the equal volume of Matrigel.  The mixture or the 
Matrigel alone was placed on the CAM of 9-day-old chicken embryos.   Tumors in the 
CAMs were photographed 5 days after the implantation.  The experiments were 
repeated two times with five embryos per each treatment and representative fields were 
photographed. (B) The relative blood vessel density was determined by measuring the 
number of blood vessel branch points in a unit area on Day 5.  Data are expressed as 
mean ±SD from replicate experiments, and normalized to results obtained from the 
CAMs implanted by Matrigel alone. (C) Tumor sections were stained by Factor VIII (Von 
Willebrand factor) antibody.  The signals were detected using the rabbit ABC staining 
system.  Negative control was the data from the sections without the primary antibody.  
The pictures were taken with an Olympus microscope at the magnification of 160×. (D) 
Two million OVCAR-3 cells expressing siSCR or sip70S6K1 were collected in 
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serum-free medium, and mixed with the equal volume of Matrigel.   The mixture or the 
Matrigel alone was placed on the CAMs of 9-day-old chicken embryos.  The tumors 
were harvested after 9 days’ incubation.  The tumors were weighed, fixed in 3.7% 
formalin in PBS, and frozen in liquid nitrogen.  Tumor sections were formalin-fixed and 
paraffin-embedded.  Representative tumor pictures were taken. (E) Tumor weight was 
obtained from ten different tumors.  The mean±SD were obtained from the ten tumors 
per treatments. (F) Tumor tissues from chicken embryos were frozen in liquid nitrogen 
and the total proteins were extracted.  Immunoblotting analysis was performed using 
antibodies against phospho-p70S6K1 (Thr421/Ser424), total p70S6K1 and β-actin.  
 
Figure 11. Sip70S6K1 expression inhibited HIF-1α and VEGF expression in tumors. 
(A) Tumor sections from cells expressing siSCR or sip70S6K1 were stained using VEGF 
antibodies.  The signals were detected using the ABC staining system.  Tumor sections 
were processed for immunohistochemical staining using monoclonal antibody against 
HIF-1α.  (B) Tumor tissues from chicken embryos were frozen in liquid nitrogen and 
the total proteins were extracted.  Immunoblotting analysis was performed using 
antibodies against HIF1-α and HIF-1β.  
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Figure 1. SiTSC1 or siTSC2 expression induced HIF-1α expression in both complete 
medium and serum-free medium. 
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Figure 2. SiTSC1 or siTSC2 expression induced VEGF protein expression and 
VEGF mRNA level in ovarian cancer cells. 
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Figure 3. Expression of siTSC1 induced p70S6K1 and ERK1/2 activation, and 
decreased levels of AKT and GSK3β phosphorylation.  
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Figure 4. Expression of siTSC2 induced p70S6K1 and ERK1/2 activation, and 
decreased levels of AKT and GSK3β phosphorylation.  
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Figure 5. SiTSC2 expression induced ovarian tumor angiogenesis through 
mTOR/p70S6K1 pathway.  
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Figure 6. SiTSC2 expression induced tumor growth in vivo. 
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Figure 7. P70S6K1 was a downstream molecule that mediated siTSC2-induced 
VEGF transcriptional activation. 
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Figure 8. Sip70S6K1 expression inhibited VEGF protein expression and VEGF 
transcriptional activation via HIF-1α DNA binding site. 
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Figure 9. Sip70S6K1 expression inhibited HIF-1α protein expression in ovarian 
cancer cells. 
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Figure 10. Sip70S6K1 expression inhibited ovarian tumor angiogenesis and tumor 
growth in CAM model. 
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Figure 11. Sip70S6K1 expression inhibited HIF-1α and VEGF expression in tumor 
sections. 
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CHAPTER IV 
 
 
 
Regulation of Survivin by PI3K/AKT /p70S6K1 Pathway and Role of Survivin in 
Ovarian Cancer 
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ABSTRACT 
 
The survivin gene is highly expressed in ovarian cancer cell lines and is a 
potential target of gene therapy for ovarian cancer.  To investigate the role of PI3K 
pathway in the regulation of survivin mRNA, we used the oncoprotein v-P3k and tumor 
suppressor gene PTEN to investigate the effects of PI3K on survivin expression.  
Overexpression of PI3K induced the expression level of survivin mRNA.  Inhibition of 
PI3K by LY294002 or overexpression of PTEN suppressed the level of survivin mRNA.  
Expression of a constitutively active form of AKT was sufficient to induce the expression 
of survivin mRNA.  To test whether p70S6K1 is a downstream target for regulating 
survivin expression, we generated a constitutively active p70S6K1 (E389D3E) construct 
by RCAS.  We found that expression of p70S6K1 increased the mRNA expression of 
survivin and rapamycin treatment decreased the survivin mRNA expression.  This study 
demonstrates that survivin mRNA is regulated by PI3K/AKT/p70S6K1 pathway.  To 
study the role of survivin in ovarian cancer cells, we established a stable cell line that 
expressed siRNA against survivin.  Expression of survivin siRNA in ovarian cancer 
cells induced apoptosis when combined with LY294002 or taxol treatment.  Survivin is 
an important downstream molecule of PI3K/AKT/p70S6K1 pathway that plays a role in 
antiapoptosis in ovarian cancer cells. 
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INTRODUCTION 
 
Apoptosis is an important process for cell and tissue homeostasis.  Apoptotic 
effector molecules and disordered apoptosis are involved in various diseases.  The 
inhibitor of apoptosis protein (IAP) inhibits apoptosis by inactivating several caspases1-4.  
Survivin is a newly described member of the IAP family 5.  Survivin can inhibit 
apoptosis by blocking a common step downstream of mitochondrial cytochrome c release 
by inhibiting terminal effector caspase-3 and caspase-7, and interfering with caspase-9 
activity and processing 6-8.  Overexpression of survivin can lead to resistance to 
apoptotic stimuli.  
Survivin is expressed primarily in fetal, but not adult tissues.  Survivin is 
constitutively expressed in most cancers, including carcinomas of the lung9, colon10,11, 
pancreas12, prostate13,14, breast15, stomach16,17, ovarian18,19 and in most hematopoietic 
malignancies20-23.  The expression of survivin is cell-cycle dependent 24.  It is 
selectively expressed at the G2/M phase of the cell cycle in a cell cycle-regulated manner 
and localized with caspase-3 to mitotic spindle microtubules 25.  Hematopoietic and 
vascular remodeling cytokines, STAT3-dependent signaling and PI3K activity influence 
survivin expression through non-cell-cycle-dependent mechanisms 26.  PI3K/AKT 
activation has been implicated in the upregulation of survivin induced by Ang-127,28, 
VEGF and GM-CSF29.  Angiopoietin-1 inhibits endothelial cell apoptosis via the 
AKT/survivin pathway 28.  VEGF binding to VEGF-R2 activates the PI3K survival 
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pathway and induces the expression of survivin in endothelial cells 30-32.  Exposure of 
human neuroblastoma cells to exogenous VEGF results in an increased expression of 
survivin protein and phosphorylated AKT, and inhibition of PI3-kinase abrogates those 
effects 33.  LY294002, the inhibitor of the PI3K pathway, inhibited survivin expression 
on GM-CSF stimulation of acute myeloid leukemia cells 29.  Inhibition of PI3K pathway 
down-regulates survivin expression and enhances TRAIL-mediated apoptosis in 
neuroblastomas 34.  Geranylgeranyltransferase I inhibitors (GGTIs) induce apoptosis in 
both cisplatin-sensitive and -resistant human ovarian epithelial cancer cells by inhibition 
of PI3K/AKT and survivin pathways 35.  Survivin expression is upregulated by 
coexpression of human epidermal growth factor receptor 2 (HER2) and epidermal growth 
factor receptor (EGFR) through PI3K/AKT signaling pathway in breast cancer cells 36.  
We hypothesize that the transcriptional regulation of survivin is regulated by 
PI3K/AKT/mTOR pathway.  In this study, we use chicken embryo fibroblast cells as a 
model to test the effect of PI3K, AKT and p70S6K1 on survivin expression. 
The targeting of survivin by antisense or dominant-negative strategies leads to the 
induction of apoptosis.  Ovarian cancer cells have a high expression of survivin.  High 
levels of survivin protein were detected in advanced ovarian carcinomas 37 and correlated 
with taxol resistance in human ovarian cancer 38.  In this study, we want to test whether 
knock-down expression of survivin by siRNA combined with PI3K inhibitor or taxol can 
regulate the apoptosis rate of ovarian cancer cells. 
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MATERIALS AND METHODS 
 
Reagents and Cell Culture― Total RNAs were isolated using the Trizol reagent from 
Invitrogen (Carlsbad, CA, USA).  The primers for the survivin and GAPDH were from 
Gene Scrip Inc (Piscataway, NJ).  The antibody against survivin was from Santa Cruz 
Biotechnology (Santa Cruz, CA) and the antibodies against phospho-Akt (Ser473), total 
Akt, p70S6K1, and phospho-p70S6K1 (Thr421/Ser424) were from Cell Signaling 
Technology (Beverly, MA).  The antibody against β-actin was from Sigma (St. Louis, 
MO).  The horseradish peroxidase (HRP)-conjugated anti-rabbit IgG and anti-mouse 
IgG were from Perkin Elmer Life Sciences (Boston, MA).  The human ovarian cancer 
cell line OVCAR-3 (American Type Culture Collection, Manassas, VA) was maintained 
in RPMI 1640 (GIBCO BRL, Grand Island, NY) supplemented with 10% FBS, 0.2% 
insulin and antibiotics at 37°C with 95% air and 5% CO2.   
 
Plasmid Constructs― SiRNA was designed using siRNA converter software (Ambion, 
Austin, TX) and the sequence was searched for homology with Basic Local Alignment 
Search Tool (BLAST) software.   The 21-mer oligonucleotides  specific to survivin 
were sense strand siRNA: UGGCGUGAACCCAGGAGGCtt  and antisense strand: 
GCCUCCUGGGUUCACGCCAtt.   Two annealed sense and antisense DNA 
oligonucleotides containing the 21-mer sequences directed against survivin were ligated 
into a pSilencer 2.1-U6 vector (Ambion, Austin, TX).  DNA oligonucleotides containing 
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the scramble sequence having no homology to any human genomes were also ligated into 
the vector and used as a control.  The plasmid that expresses siRNA against human 
survivin was named as si-survivin.   The negative control plasmid was named as siSCR.  
The plasmid constructs used are v-P3k, Myr-Akt, PTEN and PTEN mutant (C124S) 
expressed by the avian retrovirus vector RCAS as previously described 39-41.   P70S6K1 
(E389D3E) was subcloned into an adaptor vector pBSFI and then inserted into a modified 
avian retrovirus vector RCAS.Sfi.   Chicken embryo fibroblasts (CEF) were plated at 
2 × 105 cells/well in six-well plates, cultured for overnight and transfected with 2 µg of 
plasmid DNA using Lipofectamine reagent (Life Technologies, Gaithersburg, MD) per 
the instruction of the manufacturer.   After transfection, the cells were passaged for two 
weeks to ensure that the actively replicating retroviral vector spreads through the culture. 
 
Selecting a population of cells that stably express siRNA to survivin or 
siSCR―OVCAR-3 cells were plated into 6 well plates.  After cells were grown to 
50-60% confluence, 2 µg of si-survivin or siSCR was transfected into OVCAR-3 cells 
using Lipofectamine and cultured for 24 h in complete medium.  Then the cells were 
switched to medium containing 500µg/ml G418 (Sigma) and cultured for two weeks.  
The resistant cells were pooled and passaged in medium containing 250 µg/ml G418 as 
needed. 
 
RNA Isolation and RT-PCR ―Total RNAs were extracted with Trizol reagent 
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(Invitrogen).  RNA was quantitated by measuring absorbance at 260 nm.  cDNAs were 
prepared by incubating 1 µg of total RNA in 25 µl reaction buffer that has AMV Reverse 
Transcriptase, an oligo(dT) primer, RNase inhibitors and dNTP (Promega) for 60 min at 
37°C.  The cDNA fragment was amplified by PCR using following specific primers: 
survivin forward, 5’-GAG CTG CAG GTT CCTTAT C-3’; survivin reverse, 5’-ACA 
GCA TCG AGC CAA GTC AT-3’; GAPDH forward, 
5’-CCACCCATGGCAAATTCCATGGCA-3’; GAPDH reverse 
5’-TCTAGACGGCAGGTCAGGTCCACC-3’.   PCR was carried out in a thermal 
cycle programmed at 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min and amplified 
for 30 cycles.   The amplified PCR products were visualized on 2% agarose gels. 
 
Northern Blot analysis― Total RNAs were extracted using Trizol reagent according to 
manufacturer’s instruction.  Aliquots of total RNAs (10 µg) per lane were separated by 
formaldehyde gel and transferred to nylon membranes by capillary transfer with a 
downward transfer system (Schleicher & Schuell).  After UV crosslinking, the 
membranes were prehybridized for 1 h at 42°C in 10 ml of Ultrahyb buffer (Ambion).  
Then the membrane was hybridized to dCTP-32P labeled chicken survivin cDNA 
fragment, which was labeled with [α-32P] dCTP by random priming using the RadPrime 
DNA labeling system (Invitrogen) and purified with the ProbeQuant G-50 Micro 
Columns (Amersham Biosciences, Piscataway, NJ).  Signals were visualized by film 
autoradiography with an intensifying screen.  To monitor the loading of RNA and the 
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integrity of RNA, total RNAs (10 µg) were loaded on the formaldehyde gel and stained 
with ethidium bromide.   
 
Western Blotting― Cells were washed with cold PBS and collected by scraping.  They 
were lysed in ice-cold lysis buffer [150 mM NaCl, 100 mM Tris (pH 8.0), 1% Triton 
X-100, 1% deoxycholic acid, 0.1% SDS, 5 mM EDTA, and 10 mM NaF] which was 
supplemented with 1 mM sodium vanadate, 2 mM leupeptin, 2 mM aprotinin, 1 mM 
phenylmethylsulfonylfluoride, 1 mM dithiothreitol, and 2 mM pepstatin A.  After 
centrifuging at 12,000 rpm for 15 min, the supernatant was used for protein determination 
using Bio-Rad protein assay reagent (Richmond, CA).  The proteins were resolved on 
8% SDS-PAGE, transferred onto nitrocellulose membrane and incubated with antibodies 
against total AKT, phospho-AKT (Ser473), total p70S6K1, phospho-p70S6K1 
(Thr421/Ser424) and β-actin.  The membranes were washed with PBS buffer containing 
0.05% Tween 20, followed by incubation with the appropriate HRP-linked secondary 
antibodies.  The levels of specific proteins were detected with the enhanced 
chemiluminescence reagent (NEN, Boston, MA).   
 
Tunnel assay― Cells were washed 3 times in PBS and adjusted to 2x107 cells/ml.  Cells 
(100 µl/well) were transferred to a V-bottomed 96-well microplate.  A freshly prepared 
fixation solution (100 µl/well) was added to cell suspension.  Cells were resuspended 
and incubated 60 min at 15-25°C.   Fixative solution was removed by flicking off the 
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microplate.  Cells were washed once with PBS.  The microplate was centrifuged at 
300×g for 10 min.  Cells were resuspended in 100 µl /well permeabilisation solution for 
2 min on ice.  Cells were washed twice with PBS and resuspended in Tunnel reaction 
mixture.  The microplate was incubated for 30 min at 37°C in a humidified atmosphere 
in the dark.  Samples were washed twice in PBS.  Cells were transferred in a tube to a 
final volume of 250-500 µl in PBS.  Samples were analyzed by flow cytometry using an 
excitation wavelength at 540 nm and detection wavelength at 620 nm. 
Statistical Analysis—The data were analyzed using SPSS statistics software package 
(SPSS, Chicago, IL).  All of the results are expressed as mean ± SD from three 
independent experiments. The difference with P < 0.05 was considered significant.  
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RESULTS 
 
PI3K is sufficient to induce survivin mRNA expression― Among the inhibitors of 
apoptosis proteins (IAPs), survivin is an especially attracted target.  The mechanism of 
tumor-associated survivin expression is not clear.  PI3K pathway has been implicated in 
the regulation of survivin induced by growth factors.  The oncogene v-P3k codes for a 
constitutively active form of PI3K catalytic subunit.  To investigate the direct role of 
PI3K pathway in the regulation of survivin, we used the oncoprotein v-P3k to investigate 
the effects of PI3K on survivin expression.  We used the RCAS vector carrying v-P3k or 
RCAS vector to transfect CEF cells.  Overexpression of v-P3k increased the expression 
of p-Akt (Ser473) in serum starvation condition and PI3K inhibitor LY294002 treatment 
decreased the level of p-Akt (Ser473) (Fig. 1A).  Northern blot analysis demonstrated 
that v-P3k increased the level of survivin mRNA and PI3K inhibitor LY294002 inhibited 
the mRNA expression of survivin (Fig. 1B).  The tumor suppressor phosphatase and 
tensin homologue deleted on chromosome 10 (PTEN) is a phosphoinositide 3-specific 
phosphatase that dephosphorylates PtdIns(3,4,5)P3 and PtdIns(3,4)P2 to PtdIns(4,5)P2 
and PtdIns(4)P, respectively.  The mRNA expression of survivin was reduced by the 
PTEN expression and the level of survivin was not changed by the expression of PTEN 
kinase dead mutant (C124S) (Fig. 1C).  Overexpression of PTEN decreased the 
expression of p-Akt (Ser473) protein and PTEN mutant did not change the expression of 
p-Akt (Ser473) protein (Fig. 1D).  LY294002 treatment also decreased the survivin 
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mRNA expression in complete medium (Fig. 1E).  
 
AKT and p70S6K1 are downstream signaling molecules of PI3K that regulate survivin 
mRNA expression― AKT is a very important downstream target of PI3K.  Next, we 
asked whether PI3K-induced survivin expression was mediated by the activation of AKT. 
To determine whether overexpression of a constitutively active form of AKT was 
sufficient to induce the survivin mRNA, CEF cells were transfected with a constitutively 
active form of Akt (Myr-Akt) or empty vector.  Overexpression of Myr-Akt increased 
the mRNA expression of survivin.  PI3K inhibitor treatment decreased the expression of 
survivin induced by Myr-Akt expression (Fig. 2A).  Compared to vector control, 
overexpression of Myr-Akt increased the expression of p-Akt (Ser473) in serum free 
condition and the increased level of p-Akt (Ser473) protein was inhibited by LY294002 
(Fig. 2B).  This result suggested that Myr-Akt is a downstream molecule of PI3K that 
regulate survivin mRNA expression.  P70S6K1 is another downstream signaling 
molecule of PI3K and is implicated as a target of Akt.  To test whether p70S6K1 was 
involved in PI3K- and Akt-mediated survivin expression, CEF cells expressing v-P3k and 
Myr-Akt were used to test the level of p70S6K1 phosphorylation, which correlated to the 
activation of p70S6K1. Rapmycin is an inhibitor of mTOR/p70S6K1. The 
phosphorylation of p70S6K1 was analyzed in the absence or the presence of rapamycin.  
The induced activity of p70S6K1 by active forms of PI3K and Akt was inhibited by 
rapamycin in serum starvation condition (Fig. 3B and Fig. 3D).  Rapamycin treatment 
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inhibited the mRNA expression of survivin induced by v-P3k (Fig. 3A) or Myr-Akt (Fig. 
3C).  Overexpression of p70S6K1 (E389D3E) increased the expression of 
phosphorylated p70S6K1 when compared to that of RCAS control in serum-starvation 
condition.  The phosphorylation of p70S6K1 was decreased by rapamycin treatment 
(Fig. 3F).  The expression of p70S6K1 (E389D3E) in CEF cells increased the mRNA 
expression of survivin and rapamycin decreased the survivin mRNA expression (Fig. 3E). 
These results suggested that survivin mRNA expression was regulated by PI3K 
/Akt/p70S6K1 pathway. 
 
Expression of siRNA against survivin (si-survivin) in ovarian cancer cells induced 
apoptosis when combined with LY294002 or taxol treatment― Increased survivin 
expression is a negative prognostic marker in many tumors, including ovarian cancer.  
To investigate the role of survivin in ovarian cancer, we generated the ovarian cancer 
cells that stably expressed si-survivin.  Cells expressing si-survivin had a decreased 
expression of survivin mRNA when compared to that of cells expressing siSCR (Fig. 4A).  
Expression of si-survivin also decreased the expression of survivin protein (Fig. 4B).   
PI3K plays an important role in cell survival and cell growth.  It was reported that 
taxol-mediated mitotic arrest of cancer cells is associated with survivin induction, which 
preserves a survival pathway and results in resistance to taxol38,42.  To test the effect of 
PI3K inhibitor or taxol on the cell survival of ovarian cancer cells, we treated OVCAR-3 
cells expressing si-survivin or si-SCR with PI3K inhibitor or taxol in 0.5% FBS medium 
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for 24 h.  The percentage of apoptosis cells induced by PI3K inhibitor LY294002 
treatment was higher in cells expressing si-survivin than that of apoptosis cells expressing 
siSCR control cells (Fig. 4C).  Treatment with taxol increased apoptosis of OVCAR-3 
cells expressing si-survivin when compared to the cells expressing siSCR (Fig. 4D).  It 
suggested that increased levels of survivin were associated with increased resistance to 
apoptosis in ovarian cancer.   
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DISCUSSION 
           
Recent studies demonstrated that PI3K/AKT activation has been involved in the 
upregulation of survivin induced by GM-CSF29, Ang-127,28 and VEGF30,31,43.  However, 
there is no report on the direct effect of PI3K on survivin expression.  Our study 
demonstrated that survivin mRNA level is regulated by PI3K signaling pathway.  We 
used CEF cells as a cell model.  To determine if over-expression of PI3K can increase 
survivin mRNA expression, we transfected the CEF cells with v-P3k and Myr-Akt 
constructs by RCAS vector.  CEF cells over expressing v-P3k or Myr-Akt had a high 
expression of survivin mRNA when compared to RCAS vector control.  The expression 
of survivin was inhibited by inactivation of PI3K through PI3K inhibitor LY294002 or 
PTEN expression.  Overexpression of constitutively activated p70S6K1 (E389D3E) 
induced the expression of survivin.  The mRNA level of survivin was repressed by 
inhibition of mTOR activity by rapamycin.   This suggests that survivin mRNA level is 
regulated by PI3K/AKT/p70S6K1 pathway.  This is the first report that suvivin mRNA 
is regulated by PI3K/AKT/p70S6K1 pathway. 
In recent years researchers have made considerable efforts to develop strategies 
for modulating apoptosis in cancer.  In this context, approaches to inhibit survivin in 
tumor cells have been proposed with the dual aim to inhibit tumor growth through an 
increase in spontaneous apoptosis, and to enhance tumor cell response to 
apoptosis-inducing agents.  Considering that apoptosis is the primary mode of cell death 
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induced by several classes of anticancer agents and ionizing radiation, a possible general 
role of survivin in determining the chemo- and radio-sensitivity profiles of tumor cells 
has been hypothesized38,42,44,45.  Moreover, since survivin is associated with 
microtubules and with the mitotic spindle it is likely that this protein can specifically 
contribute to the response of cells to microtubule-interacting agents.  It is recently 
reported that transfection of wild-type survivin efficiently protected murine NIH3T3 
fibroblasts from apoptosis induced by the microtubule-stabilizing agent taxol25.  In 
agreement with this observation, infection of HeLa cells with an adenoviral vector 
expressing survivin suppressed apoptosis induced by taxol46.  Based on this finding, our 
laboratory performed a parallel investigation on an ovarian cancer cell lines to determine 
whether survivin is involved in regulating cell sensitivity to taxol.  Our finding is that 
expression of siRNA specific to survivin in ovarian cancer cells induces more apoptosis 
when combined with LY294002 or taxol treatment than cells expressing siSCR alone 
treated with LY294002 or taxol.  Treatment with survivin siRNA and inhibitors of PI3K 
or taxol may provide potential novel therapeutic options to treat ovarian cancer. 
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FIGURE LEGENDS 
 
Fig. 1. PI3K is sufficient to induce survivin mRNA expression. (A) The transfected CEF 
cells were treated without or with 10 µM LY294002 in serum-free medium for 1 h.  The 
total cellular protein extracts were prepared and subjected to immunoblotting analysis 
using antibody specific to phosphorylation of Akt (Ser473) and total Akt. (B) RCAS 
alone or RCAS carrying v-P3k or was transfected into CEF cells and cultured for two 
weeks.  Cells were cultured to 80% confluence, and then changed to serum-free medium 
for 8 h.  Total RNAs (10 µg) were analyzed by Northern blotting. (C) RCAS carrying 
PTEN or PTEN mutant (C124S) was transfected into CEF cells and cultured for two 
weeks.  Cells were cultured to 80% confluence and then changed to serum-free medium 
for 8 h.  Total RNAs (10 µg) were analyzed by Northern blotting. (D) The level of Akt 
phosphorylation at Ser-473 or total Akt was detected by immunoblotting using 
phospho-Akt (Ser-473) or total Akt antibodies. (E) CEF cells expressing RCAS vector 
control were cultured in complete medium until 70-80% confluence and then treated with 
10 µM LY294002 for 8 h.  Total RNAs (10 µg) were analyzed by Northern blotting. (F) 
CEF cells expressing RCAS vector control were cultured in complete medium until 
70-80% confluence, changed to serum-free medium for 12 h and then treated with 
complete medium without or with 10 µM LY294002 for 1 h.  Total cellular extracts 
were prepared and subjected to immunoblotting using anti-phospho-Akt at Ser-473 and 
anti-Akt antibodies. 
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Fig. 2.  Akt is a downstream signaling molecule of PI3K that regulates survivin mRNA 
expression. (A) RCAS empty vector alone or RCAS carrying Myr-Akt was transfected 
into CEF cells and cultured for two weeks.  Cells were cultured to 80% confluence and 
then changed to serum-free medium for 8 h.  The cells that transfected with Myr-Akt 
were treated with 10 µM LY294002 in serum-free medium for 8 h.  The mRNA level of 
survivin was detected by Northern blotting. (B) CEF cells were transfected with RCAS 
carrying Myr-Akt or empty vector alone and cultured for two weeks.  The CEF cells 
transfected with Myr-Akt or RCAS vector were serum starved for 12 h.  Then the CEF 
cells transfected with Myr-Akt were incubated in the presence or absence of 10 µM or 20 
µM LY294002 for 1h.  The levels of phosphorylation of Akt at Ser-473 and total Akt 
were determined by immunoblotting.  
 
Fig. 3. PI3K/Akt upregulates survivin mRNA expression through p70S6K1. (A) RCAS 
vector alone or RCAS carrying v-P3k was transfected into CEF cells and cultured for two 
weeks.  Cells expressing RCAS were cultured to 80% confluence and then changed to 
serum-free medium for 8 h.  The cells that transfected with v-P3k were treated with or 
without 10 nM rapamycin in serum-free medium for 8 h.  The expression of survivin 
was determined by Northern blotting as described in Materials and Methods. (B) CEF 
cells were transfected with v-P3k or empty vector and treated without or with 10nM 
rapamycin in serum-free medium for 1 h.  Proteins of these transfected cells were 
 176
detected by immunoblotting using antibody specific to phosphorylation of p70S6K1 at 
Thr-421/Ser-424 and total p70S6K1. (C) RCAS empty vector alone or RCAS carrying 
Myr-Akt was transfected into CEF cells and cultured for two weeks.  Cells expressing 
RCAS were cultured to 80% confluence and then changed to serum-free medium for 8 h.  
The cells that transfected with Myr-Akt were treated with 10 nM rapamycin in serum-free 
medium for 8 h.  The expression of survivin was determined by Northern blotting as 
described in Materials and Methods. (D) CEF cells were transfected with empty vector or 
Myr-Akt and serum starved for 12 h.  The cells that transfected with Myr-Akt treated 
with or without 10 nM rapamycin for 1 h.  The activation of p70S6K1 was detected by 
immunoblotting using the antibody specific to phospho-p70S6K1 at Thr-421/Se-r424 and 
total p70S6K1. (E) RCAS empty vector alon or RCAS carrying p70S6K1 (E389D3E) 
was transfected into CEF cells and cultured for one week.  The cells transfected with 
vector alone were cultured to 80% confluence, then changed to serum-free medium for 8 
h.  The cells that transfected with p70S6K1 (E389D3E) were treated with or without 10 
nM rapamycin in serum-free medium for 8 h.  The mRNA level of survivin was 
measured by Northern blotting. (F) CEF cells transfected with empty vector or p70S6K1 
(E389D3E) were treated without or with 10 nM rapamycin in serum-free medium for 1 h.  
The phosphorylation of p70S6K1 at Thr-421/Se-r424 was determined by immunoblotting 
analysis using an antibody specific to phosphorylated p70S6K1 at Thr-421/Se-r424.  
The level of total p70S6K1 was determined by immunoblotting analysis using an 
antibody specific to p70S6K1. 
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Fig. 4.  Expression of siRNA against survivin in ovarian cancer cells induces apoptosis 
when combined with LY294002 or taxol treatment. (A) Generation of cells stably 
expressing si-survivin.  The si-survivin and siSCR were transfected into OVCAR-3 cells 
by Lipofectamine.  After two weeks selection in medium containing 500 µg/ml G418, 
the clones stably expressing the siRNA were picked and cultured in fresh culture dishes.  
Cells expressing si-survivin or siSCR were cultured at a density of 5×105 cells/dish in 
RPMI 1640 medium with 10% FBS for 24 h at 37°C in 5% CO2 incubator.  The total 
RNAs were prepared and first strand cDNAs was synthesized using AMV and oligo(dT) 
primer.  Survivin mRNA level in OVCAR-3 cells expressing si-survivin and siSCR was 
assayed by RT-PCR.  The survivin mRNA level was compared with the signal from 
control GAPDH mRNA level.  PCR products (10µl) of siSCR and si-survivin were run 
on 2% agrose gel.  Pictures were taken using Eagleeye system. (B) Cells expressing 
si-survivin or siSCR were cultured to 80% confluence in normal medium and lysed, and 
50 µg of protein was analyzed by immunoblotting with the antibodies against survivin 
and β-actin. (C) OVCAR-3 cells that express si-survivin or siSCR were cultured to 
50-60% confluence.  Cells were changed to 0.5% fetal bovine serum and treated without 
or with 20 µM LY294002 for 24 h.  Cells were washed with 1×PBS, fixed in 4% fresh 
paraformaldehyde, permeabilized by 0.1% Triton X-100 and labeled by Terminal 
deoxynucleotidyl transferase from calf thymus. * indicates a significant difference from 
the siSCR treated with LY294002 group (p < 0.05). (D) Cells were changed to 0.5% fetal 
bovine serum and treated without or with 0.5µM taxol for 24 h.  Cells were washed with 
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1×PBS, fixed in 4% fresh paraformaldehyde, permeabilized by 0.1% Triton X-100 and 
labeled by Terminal deoxynucleotidyl transferase from calf thymus.  Samples were 
analyzed by flow cytometry use an excitation wavelength in the range of 520-560 nm 
(maximum 540 nm; green) and detection in the range of 570-620 nm (maximum 580 nm, 
red).  * indicates a significant difference from the siSCR treated with taxol group (p < 
0.05). 
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Fig. 1. PI3K is sufficient to induce survivin mRNA expression. 
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Fig. 2.  Akt is a downstream signaling molecule of PI3K that regulates survivin mRNA 
expression. 
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Fig. 3. PI3K/Akt upregulates survivin mRNA expression through p70S6K1. 
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Fig. 4.  Expression of siRNA specific to survivin in ovarian cancer cells induces 
apoptosis when combined with LY294002 or taxol treatment. 
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CHAPTER V       
 
 
 
Summary and Conclusions 
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The PI3K signaling pathway has previously been implicated in tumorigenesis, 
and recent studies suggest a pivotal role of PI3K catalytic subunit in human cancers.  
The PIK3CA gene, encoding the p110 alpha catalytic subunit of PI3K, is frequently 
mutated in human cancer.  Both mutational and functional analyses have shown that 
PIK3CA is an oncogene that plays an important role in tumor progression1,2.  
LY294002 and wortmannin are two widely used PI3K inhibitors that inhibit the 
catalytic activity of PI3K.  However, there are three major classes of PI3K isoforms 
existing in the cells3 and LY294002 has a broad inhibitory effect against all class І 
PI3Ks as well as other kinases such as ATM and ATR4.  Wortmannin is a fungal 
metabolite that irreversibly inhibits p110 by reacting covalently with the catalytic site.  
Thus, in this study we wanted to specifically inhibit the p110α subunit of PI3K by 
small interfering RNA (siRNA) in ovarian cancer cells.  Expression of p110α siRNA 
significantly decreased cell migration, invasion, and proliferation in contrast to the 
siSCR control cells.  AKT is the primary downstream mediator of the effects of 
PI3K.  AKT has three different isoforms: AKT1, AKT2 and AKT3.  The three AKT 
isoforms are broadly expressed, although isoform-specific patterns of expression can 
exist in some tissues.  It is reported that the isoforms AKT1 and AKT2 were 
expressed at the mRNA level in ovarian cancer cell lines, while no relevant AKT3 
mRNA levels were detected in ovarian caner cell lines5.  Among the specific AKT 
isoforms, increased AKT1 kinase activity has been reported in breast and ovarian 
cancers6.  In our study, we utilized siRNA to knockdown the expression of AKT1 
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isoform and determined the role of AKT1 in ovarian caner cells.  We found that 
inhibition of AKT1 is sufficient to decrease cell migration, invasion, and proliferation 
in ovarian cancer cells.  Ribosomal S6 kinase is activated by PI3K/AKT pathway.  
The activity of p70S6K1 is inhibited in cells expressing siRNA specific to p110α and 
AKT1.  To study the role of p70S6K1 in ovarian cancer progression, we also 
designed siRNA specific to p70S6K1 and established stable cell lines that expressed 
p70S6K1 siRNA.  Downregulation of p70S6K1 activity by p70S6K1 siRNA also 
decreased cell migration, invasion, and proliferation associated with the induction of 
p27KIP1 levels.  The study in Chapter II suggests that PI3K/AKT/mTOR/p70S6K1 
pathway is critical for OVCAR-3 cell proliferation, migration and invasion.  
Inhibition of PI3K/AKT/mTOR/p70S6K1 pathway could reduce proliferation and 
metastasis of tumor cells.  They are ideal targets for the development of small 
molecule inhibitors for potential clinical application.   
The invasion process is comprised of distinct events, which include the 
attachment of cells to the basement membrane, secretion of enzymes that degrade the 
basement membrane, and the migration of cells into the target tissue in response to 
specific chemotactic stimuli7.  Several lines of evidence suggested that the 
mechanism by which PI3K/AKT/p70S6K1 pathway contributes to ovarian cancer cell 
migration and invasion involves the matrix metalloproteinases (MMPs), a group of 
zinc-dependent ECM-degrading enzymes.  MMPs are thought to play a critical role 
in tumor cell invasion8.  The ratio of MMP-9: MMP-2 is increased in ovarian tumor 
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tissue compared with normal ovaries9.  The elevated levels of MMP-9 protein have 
been detected in invasive epithelial ovarian carcinoma patient specimens10.  Basal 
and EGF-induced MMP-9 protein expression involves both PI3K and MAPK 
signaling in ovarian cancer cells11.  AKT increased HT1080 invasion, by increasing 
cell motility and MMP-9 production12.  The increase of MMP-9 production was 
mediated by activation of nuclear factor-κB transcriptional activity by AKT.  
HGF-induced invasion and migration is mediated by p70S6K1 through regulation of 
MMP in response to PI3K/Akt signaling13.  P70S6K1 was found to be a direct 
transcriptional activator of MMP-9 synthesis.  In the future, we can use our system 
to determine the role of PI3K/AKT/p70S6K1 in MMP-2 or MMP-9 expression in 
ovarian cancer cells. 
The mammalian target of rapamycin (mTOR) mediates cell growth by 
stimulating protein synthesis.  It is known that mTOR is a downstream target of 
AKT in vitro14.  However, it is unknown how AKT activates mTOR in vivo.  The 
tuberous sclerosis 2 complex (TSC2) protein has been the subject of much recent 
interest because it links AKT to mTOR in vivo.  The TSC1 and TSC2 proteins form 
a complex in vivo.  Several groups have demonstrated that TSC2 is phosphorylated 
and inhibited by AKT15,16.  TSC1/TSC2 complex impedes signaling by mTOR due 
to the TSC2 GTPase-activating protein (GAP) activity towards the Ras family small 
GTPase Rheb17.  AKT phosphorylates TSC2 and disrupts its interaction with TSC1.  
This leads to increased levels of GTP-bound Rheb, which results in the activation of 
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the mTOR/p70S6K/eIF4E pathway.  A common feature of TSC patient is cutaneous 
angiofibromas and renal angiomyolipomas18.  TSC2 regulates VEGF through 
mTOR-dependent and independent pathway19.  The role of TSC1 and TSC2 in 
tumor angiogenesis is not known yet.  In this study, we study the function of TSC1 
and TSC2 in regulating HIF-1α and VEGF in ovarian cancer cells.  It was reported 
that Tsc2-null cells had higher levels of HIF-1α mRNA and protein than Tsc2+/+ cells.  
We showed that the protein level of HIF-1α was induced in cells expressing siTSC1 
or siTSC2 in both complete medium or serum free medium under normoxia condition.  
Further experiments will be performed to study whether TSC1 or TSC2 regulates 
HIF-1α mRNA expression or affects protein stability in ovarian cancer cells.  In this 
study, we showed that inhibition of TSC1 or TSC2 induced VEGF protein and mRNA 
expression, and induced tumor growth and angiogenesis in vivo.  The induction of 
tumor growth and angiogenesis is significantly decreased by mTOR inhibitor 
rapamycin or p70S6K1 dominant negative construct.  These data are consistent with 
our hypothesis that downregulation of TSC2 results in activation of mTOR/p70S6K1, 
which increases HIF-1α and VEGF expression that may regulate tumor growth and 
angiogenesis.  We showed that p70S6K1 was a downstream molecule of TSC1 or 
TSC2 that regulated VEGF transcriptional activation.  To test the direct role of 
p70S6K1 in tumor angiogenesis, we showed that specifically knockdown of p70S6K1 
expression decreased ovarian cancer tumor growth and angiogenesis in vivo.  We 
demonstrated that inhibition of p70S6K1 expression decreased VEGF expression at 
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the transcriptional level in ovarian cancer cells.  P70S6K1 regulated VEGF 
transcriptional activation through HIF-1α, but not HIF-1β subunit expression.  We 
also showed that p70S6K1 was required for VEGF and HIF-1α expression in tumor 
tissues.  We showed here for the first time that p70S6K1 down-regulation inhibited 
expression of VEGF at the transcriptional level through HIF-1α expression and 
inhibition of p70S6K1 expression decreased ovarian tumor growth and angiogenesis 
in vivo.  This novel finding provides a molecular basis for potentially targeting 
p70S6K1 for human ovarian cancer therapy in the future.  
In addition, survivin gene is highly expressed in ovarian cancer cell lines and 
is a potential target for ovarian cancer.  Expression of siRNA specific to survivin in 
ovarian cancer cells induces apoptosis when combined with LY294002 or taxol 
treatment.  Our study demonstrates that suvivin mRNA is regulated by 
PI3K/AKT/p70S6K1 pathway.  Survivin is an important downstream molecule of 
PI3K/AKT/p70S6K1 pathway that plays a role in antiapoptosis in ovarian cancer 
cells.  
The last figure is the summary of this study.  PI3K is activated by upstream 
activators including oncogenes and growth factors or is constitutively activated in 
ovarian cancer through PI3K gene amplification or mutations. Activated PI3K 
transmits signals to its downstream target AKT, which phosphorylates TSC2 and 
inactivates it.  Inhibition of TSC2 induces activation of mTOR which regulates 
p70S6K1.  Knock-down expression of TSC2 increases tumor growth through 
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pathways as follows: TSC2/mTOR/p70S6K1 pathway or TSC2/MAPK pathway.  
Inhibition of TSC2 increased protein expression of HIF-1 and VEGF.  TSC2 may 
regulate HIF-1 protein expression through p70S6K1 or ERK1/2.  Activated 
p70S6K1 induces the transcriptional activation of VEGF through HIF-1α expression 
to increase tumor angiogenesis.  P70S6K1 is also an important downstream 
signaling molecule that mediates PI3K and AKT induced cell migration, invasion, 
proliferation and cell cycle progression.  Survivin is another molecule that has 
important role in tumor progression.  Survivin expression is regulated by 
PI3K/AKT/p70S6K1 pathway and survivin may regulate tumor growth through its 
antiapoptosis role in ovarian cancer. 
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Figure Schematic representation of PI3K/AKT/TSC2/p70S6K1 induced tumor 
angiogenesis and tumor growth. 
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